Document:

Second Supplemental Indenture

 Exhibit 4.1 
 EXECUTION VERSION 
 AMERISOURCEBERGEN CORPORATION 

and 

each of the Guarantors named herein 
 $500,000,000 
 3.500% SENIOR NOTES DUE 2021 

 
  

SECOND SUPPLEMENTAL INDENTURE 
 Dated as of November 14, 2011 
 To 

INDENTURE 

Dated as of November 19, 2009 
  

 
 U.S. BANK
NATIONAL ASSOCIATION, 
 as Trustee 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	  	 	2	  
			
	 Section 1.01.
	  	 Definitions
	  	 	2	  
			
	 Section 1.02.
	  	 Notices, etc., to Trustee and Company
	  	 	18	  
			
	 Section 1.03.
	  	 Conflict with Trust Indenture Act
	  	 	18	  
			
	 Section 1.04.
	  	 Effect of Headings and Table of Contents
	  	 	19	  
			
	 Section 1.05.
	  	 Successors and Assigns
	  	 	19	  
			
	 Section 1.06.
	  	 Severability Clause
	  	 	19	  
			
	 Section 1.07.
	  	 Benefits Of Indenture
	  	 	19	  
			
	 Section 1.08.
	  	 Governing Law
	  	 	19	  
			
	 Section 1.09.
	  	 Counterparts
	  	 	19	  
			
	 Section 1.10.
	  	 Immunity of Incorporators, Stockholders, Directors and Officers
	  	 	19	  
			
	 Section 1.11.
	  	 Qualification of Indenture
	  	 	20	  
			
	 Section 1.12.
	  	 Relationship with Base Indenture
	  	 	20	  
		
	 ARTICLE 2 THE 2021 NOTES
	  	 	20	  
			
	 Section 2.01.
	  	 Form of 2021 Note
	  	 	20	  
			
	 Section 2.02.
	  	 Designation and Principal Terms
	  	 	20	  
			
	 Section 2.03.
	  	 Denominations
	  	 	21	  
			
	 Section 2.04.
	  	 Global Form
	  	 	21	  
			
	 Section 2.05.
	  	 Depositary
	  	 	21	  
			
	 Section 2.06.
	  	 Execution, Authentication and Delivery, and Dating
	  	 	21	  
			
	 Section 2.07.
	  	 CUSIP Number
	  	 	23	  
			
	 Section 2.08.
	  	 Issuance of Additional 2021 Notes
	  	 	23	  
		
	 ARTICLE 3 REMEDIES
	  	 	24	  
			
	 Section 3.01.
	  	 Events of Default
	  	 	24	  
			
	 Section 3.02.
	  	 Action by Holders
	  	 	25	  
		
	 ARTICLE 4 SUPPLEMENTAL INDENTURES
	  	 	26	  
			
	 Section 4.01.
	  	 Supplemental Indentures Without Consent of Securityholders
	  	 	26	  
			
	 Section 4.02.
	  	 Supplemental Indentures With Consent of Securityholders
	  	 	27	  
			
	 Section 4.03.
	  	 Execution of Supplemental Indentures
	  	 	28	  
			
	 Section 4.04.
	  	 Effect of Supplemental Indentures
	  	 	28	  

  
 -i-

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
			
	 Section 4.05.
	  	 Conformity With Trust Indenture Act
	  	 	28	  
			
	 Section 4.06.
	  	 Reference in 2021 Notes to Supplemental Indentures
	  	 	28	  
		
	 ARTICLE 5 COVENANTS
	  	 	29	  
			
	 Section 5.01.
	  	 Payment of Principal, Premium and Interest
	  	 	29	  
			
	 Section 5.02.
	  	 Liens
	  	 	29	  
			
	 Section 5.03.
	  	 Limitation on Sale and Leaseback Transactions
	  	 	29	  
			
	 Section 5.04.
	  	 Offer to Repurchase Upon Change of Control
	  	 	29	  
			
	 Section 5.05.
	  	 Additional 2021 Note Guarantees
	  	 	31	  
			
	 Section 5.06.
	  	 Designation of Restricted and Unrestricted Subsidiaries
	  	 	31	  
			
	 Section 5.07.
	  	 SEC Reports
	  	 	31	  
		
	 ARTICLE 6 SUCCESSORS
	  	 	32	  
			
	 Section 6.01.
	  	 Merger, Consolidation or Sale of Assets
	  	 	32	  
		
	 ARTICLE 7 REDEMPTION OF 2021 NOTES BY COMPANY
	  	 	33	  
			
	 Section 7.01.
	  	 Optional Redemption
	  	 	33	  
			
	 Section 7.02.
	  	 Mandatory Redemption
	  	 	33	  
		
	 ARTICLE 8 2021 NOTE GUARANTEES
	  	 	33	  
			
	 Section 8.01.
	  	 Guarantee
	  	 	33	  
			
	 Section 8.02.
	  	 Limitation on Guarantor Liability
	  	 	35	  
			
	 Section 8.03.
	  	 Execution and Delivery of 2021 Note Guarantee
	  	 	35	  
			
	 Section 8.04.
	  	 Guarantors May Consolidate, etc., on Certain Terms
	  	 	35	  
			
	 Section 8.05.
	  	 Releases
	  	 	36	  

  
 -ii-

 THIS SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”),
by and among AmerisourceBergen Corporation, a Delaware corporation (hereinafter called the “Company”), the Guarantors (as hereinafter defined) and U.S. Bank National Association, a national banking association organized and existing
under the laws of the United States of America, as trustee (hereinafter called the “Trustee”), is made and entered into as of this 14th day of November, 2011. 
 Recitals 
 The Company has heretofore executed and delivered to the Trustee
an indenture, dated as of November 19, 2009 (as such indenture may be amended, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Base Indenture”), providing for the issuance of the
Company’s unsecured debentures, notes, bonds, and other evidences of indebtedness, to be issued in one or more fully registered series (the “Securities”). 

Pursuant to Section 3.01 of the Base Indenture, the Company desires to provide for the establishment of a new series of Securities
under the Base Indenture to be known as its “3.500% Senior Notes due 2021” (the “2021 Notes”), the form and substance and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and
this Supplemental Indenture. 
 The Guarantors desire to guarantee the Company’s payment obligations under the 2021 Notes
in the manner set forth herein (each a “2021 Note Guarantee”). 
 The Company and the Guarantors have requested
that the Trustee execute and deliver this Supplemental Indenture, which is being entered into pursuant to the provisions of Section 9.01 of the Base Indenture. 
 All conditions and requirements necessary to make this Supplemental Indenture a valid, binding and legal instrument in accordance with its terms have been performed and fulfilled by the parties hereto and
the execution and delivery thereof have been in all respects duly authorized by the parties hereto. 
 This Supplemental
Indenture shall modify the Base Indenture only with respect to the 2021 Notes and the related 2021 Note Guarantees. 

Agreements of the Parties 
 To set forth or to provide for the establishment of the terms and conditions upon which the 2021 Notes are and are to be authenticated, issued, and delivered, and in consideration of the premises thereof,
and the purchase of the 2021 Notes by the Holders thereof, the Company, the Guarantors and the Trustee mutually covenant and agree as follows, for the equal and proportionate benefit of all Holders from time to time of the 2021 Notes: 

  
 1 

 ARTICLE 1 
 Definitions and Other Provisions of General Application 

Section 1.01. Definitions. For all purposes of this Supplemental Indenture and of any indenture supplemental
hereto, except as expressly provided or unless the context otherwise requires: 
 (a) the capitalized terms used in this
Supplemental Indenture and not otherwise defined herein have the meanings assigned to them in the Base Indenture; 
 (b) all
other terms used in this Supplemental Indenture which are not defined in this Supplemental Indenture or in the Base Indenture and that are defined in the Trust Indenture Act, either directly or by reference therein, have the meanings assigned to
them therein; 
 (c) all accounting terms not otherwise defined in this Supplemental Indenture have the meanings assigned to
them in accordance with GAAP (as hereinafter defined); 
 (d) all references in this Supplemental Indenture to designated
“Articles”, “Sections” and other subdivisions are to the designated Articles, Sections and other subdivisions of this instrument as originally executed, unless the context indicates otherwise. The words
“herein”, “hereof”, and “hereunder” and other words of similar import refer to this Supplemental Indenture as a whole and not to any particular Article, Section, or other subdivision; 

(e) “or” has the inclusive meaning attributable to the phrase “and/or”; 

(f) “including” has the inclusive meaning attributable to the phrase “but not limited to”; 

(g) words in the singular include the plural, and in the plural include the singular; 

(h) provisions apply to successive events and transactions; 
 (i) references to sections of or rules under the Securities Act will be deemed to include substitute, replacement or successor sections or rules adopted by the Commission from time to time; and

 (j) “will” shall be interpreted as an express command. 

“2021 Note Guarantee” has the meaning assigned to it in the preamble of this Supplemental Indenture. 

“2021 Notes” has the meaning assigned to it in the preamble to this Supplemental Indenture. The Initial 2021 Notes and
the Additional 2021 Notes shall be treated as a single class for purposes of certain matters specified in this Supplemental Indenture. 
 “Additional 2021 Notes” means any Securities (other than the Initial 2021 Notes) issued under this Supplemental Indenture in accordance with Section 2.08 hereof, as part of the same
series as the Initial 2021 Notes. 

  
 -2-

 “Adjusted Treasury Rate” means, with respect to any Redemption Date, the
rate per annum equal to the semiannual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for
such Redemption Date (or, in the case of either defeasance or covenant defeasance to a Redemption Date, for the applicable date of deposit with the Trustee of funds to pay the Redemption Price), plus 25 basis points. 

“Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under
direct or indirect common control with such specified Person. For purposes of this definition, “control,” as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of
the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise; provided that beneficial ownership of 10% or more of the Voting Stock of a Person will be deemed to be control. For
purposes of this definition, the terms “controlling,” “controlled by” and “under common control with” have correlative meanings. No Person (other than the Company or any Subsidiary of the Company) in whom a Receivables
Subsidiary makes an Investment in connection with a Qualified Receivables Transaction will be deemed to be an Affiliate of the Company or any of its Subsidiaries solely by reason of such Investment. 

“Asset Sale” means the sale, lease, conveyance or other disposition of any assets or rights, other than sales or returns
of inventory in the ordinary course of business (provided that the sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company and its Restricted Subsidiaries taken as a whole shall be governed by the
provisions of Section 6.01 hereof). 
 “Attributable Indebtedness” in respect of a sale and leaseback
transaction means, at the time of determination, the present value of the obligation of the lessee for net rental payments during the remaining term of the lease included in such sale and leaseback transaction including any period for which such
lease has been extended or may, at the option of the lessor, be extended. Such present value shall be calculated using a discount rate equal to the rate of interest implicit in such transaction, determined in accordance with GAAP. 

“Bankruptcy Law” means Title 11, U.S. Code or any similar federal or state law for the relief of debtors. 

“Base Indenture” has the meaning set forth in the preamble to this Supplemental Indenture. 

“Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except
that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such “person” will be deemed to have beneficial ownership of all securities that such
“person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition. The terms “Beneficially Owns” and
“Beneficially Owned” have a corresponding meaning. 
 “Blanco” means J.M. Blanco, Inc. 

  
 -3-

 “Board of Directors” means (i) with respect to a corporation, the
Board of Directors of the corporation or any authorized committee of the Board of Directors, (ii) with respect to a partnership, the Board of Directors of the general partner of the partnership; and (iii) with respect to any other Person,
the board or committee of such Person serving a similar function. 
 “Board Resolution” means a copy of a
resolution certified by the Secretary or an Assistant Secretary of any Person to have been duly adopted by any Board of Directors or any duly authorized committee thereof and to be in full force and effect on the date of such certification, and
delivered to the Trustee. 
 “Business Day” means each Monday, Tuesday, Wednesday, Thursday and Friday that is
not a day on which banking institutions in the Place of Payment are authorized or obligated by law to close. 
 “Capital
Lease Obligation” means, at the time any determination thereof is to be made, the amount of the liability in respect of a capital lease that would at such time be required to be capitalized on a balance sheet in accordance with GAAP.

 “Capital Stock” means 
 (i) in the case of a corporation, corporate stock, 
 (ii) in the case of
an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock, 
 (iii) in the case of a partnership or limited liability company, partnership or membership interests (whether general or limited), and 

(iv) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or
distributions of assets of, the issuing Person, other than earnouts. 
 “Chairman” means the Chairman of any
Person’s Board of Directors. 
 “Change of Control” means the occurrence of any of the following:

 (a) the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or
consolidation), in one or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries taken as a whole to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act)
other than to the Company or one of its Subsidiaries; 
 (b) the consummation of any transaction (including without limitation,
any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange
Act), directly or indirectly, of more than 50% of the outstanding Voting Stock of the Company, measured by voting power rather than number of shares; 

  
 -4-

 (c) the Company consolidates with, or merges with or into, any Person, or any Person
consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of the outstanding Voting Stock of the Company or such other Person is converted into or exchanged for cash, securities or other
property, other than any such transaction where the shares of the Voting Stock of the Company outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving
Person immediately after giving effect to such transaction; 
 (d) the first day on which the majority of the members of the
Board of Directors of the Company cease to be Continuing Directors; or 
 (e) the adoption of a plan relating to the liquidation
or dissolution of the Company. 
 “Change of Control Offer” has the meaning specified in Section 5.04
hereof. 
 “Change of Control Payment” has the meaning specified in Section 5.04 hereof. 

“Change of Control Payment Date” has the meaning specified in Section 5.04 hereof. 

“Change of Control Triggering Event” means the 2021 Notes cease to be rated Investment Grade by at least two of the
three Rating Agencies on any date during the period (the “Trigger Period”) commencing 60 days prior to the first public announcement by the Company of any Change of Control (or pending Change of Control) and ending 60 days following
consummation of such Change of Control (which Trigger Period will be extended following consummation of a Change of Control for so long as any of the Rating Agencies has publicly announced that it is considering a possible ratings change). Unless at
least two of the three Rating Agencies are providing a rating for the 2021 Notes at the commencement of any Trigger Period, the 2021 Notes will be deemed to have ceased to be rated Investment Grade by at least two of the three Rating Agencies during
that Trigger Period. Notwithstanding the foregoing, no Change of Control Triggering Event will be deemed to have occurred in connection with any particular Change of Control unless and until such Change of Control has actually been consummated.

 “Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment
Banker as having a maturity comparable to the remaining term of the 2021 Notes that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable
maturity to the remaining term of the 2021 Notes. 
 “Comparable Treasury Price” means, with respect to any
Redemption Date, (A) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (B) if the Trustee obtains fewer than three such
Reference Treasury Dealer Quotations, the average of all such Quotations. 

  
 -5-

 “Consolidated Cash Flow” means, with respect to any specified Person for
any period, the Consolidated Net Income of such Person for such period plus: 
 (a) an amount equal to any extraordinary
loss plus any net loss realized by such Person or any of its Restricted Subsidiaries in connection with an Asset Sale, to the extent such losses were deducted in computing such Consolidated Net Income; plus 

(b) provision for taxes based on income or profits of such Person and its Restricted Subsidiaries for such period, to the extent that
such provision for taxes was deducted in computing such Consolidated Net Income; plus 
 (c) consolidated interest
expense of such Person and its Restricted Subsidiaries for such period, whether paid or accrued and whether or not capitalized (including, without limitation, amortization of debt issuance costs and original issue discount, non-cash interest
payments, the interest component of any deferred payment obligations, the interest component of all payments associated with Capital Lease Obligations, imputed interest with respect to Attributable Indebtedness, commissions, discounts and other fees
and charges incurred in respect of letter of credit or bankers’ acceptance financings, and net of the effect of all payments made or received pursuant to Hedging Obligations), to the extent that any such expense was deducted in computing such
Consolidated Net Income; plus 
 (d) depreciation, amortization (including amortization of goodwill and other intangibles
but excluding amortization of prepaid cash expenses that were paid in a prior period) and other non-cash expenses (excluding any such non-cash expense to the extent that it represents an accrual of or reserve for cash expenses in any future period
or amortization of a prepaid cash expense that was paid in a prior period) of such Person and its Restricted Subsidiaries for such period to the extent that such depreciation, amortization and other non-cash expenses were deducted in computing such
Consolidated Net Income; plus 
 (e) all nonrecurring and unusual charges (including, without limitation, restructuring,
shutdown, severance and facility consolidation costs) taken by the Company related to the business transformation project to implement an enterprise resource planning system; minus 

(f) non-cash items increasing such Consolidated Net Income for such period, other than the accrual of revenue in the ordinary course of
business, 
 in each case, on a consolidated basis and determined in accordance with GAAP. 

“Consolidated Net Income” means, with respect to any specified Person for any period, the aggregate of the Net Income of
such Person and its Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP; provided that: 
 (a) the Net Income or loss of any Person that is not a Subsidiary or that is accounted for by the equity method of accounting will be included only to the extent of the amount of dividends or
distributions paid in cash to the specified Person or a Restricted Subsidiary of the Person; 

  
 -6-

 (b) the Net Income of any Restricted Subsidiary will be excluded to the extent that the
declaration or payment of dividends or similar distributions by that Restricted Subsidiary of that Net Income is not at the date of determination permitted without any prior governmental approval (that has not been obtained) or, directly or
indirectly, by operation of the terms of its charter or other governing instrument or any judgment, decree, order, statute, rule or governmental regulation applicable to that Restricted Subsidiary or its stockholders; 

(c) the cumulative effect of a change in accounting principles will be excluded; 

(d) to the extent deducted in the calculation of Net Income, any non-recurring charges associated with any premium or penalty paid,
write-offs of deferred financing costs or other financial recapitalization charges in connection with redeeming or retiring any indebtedness prior to its Stated Maturity will be added back to arrive at Consolidated Net Income; and 

(e) the Net Income (but not loss) of any Unrestricted Subsidiary will be excluded (except to the extent distributed to the Company or one
of its Restricted Subsidiaries). 
 “Consolidated Net Worth” means, with respect to any Person, the total of
the amounts shown on such Person’s and its consolidated Subsidiaries’ balance sheet, determined on a consolidated basis in accordance with GAAP, as of the end of the most recent fiscal quarter for which internal financial statements are
available prior to the taking of any action for purpose of which the determination is being made, as the sum of (i) the par or stated value of all such Person’s Capital Stock, plus (ii) paid-in-capital or capital surplus relating to
such Capital Stock, plus (iii) any retained earnings or earned surplus, minus (iv) any accumulated deficit, minus (v) any amounts attributable to Disqualified Stock. 

“Continuing Directors” means, as of any date of determination, any member of the Board of Directors of the Company who
(i) was a member of such Board of Directors on the date of this Supplemental Indenture or (ii) was nominated for election or elected to such Board of Directors with the approval of a majority of the Continuing Directors who were members of
such Board at the time of such nomination or election. 
 “Credit Agreement” means the Credit Agreement dated
as of March 18, 2011, as amended and restated as of October 28, 2011, among the Company, the lenders party thereto, JPMorgan Chase Bank N.A., as administrative agent and the other financial institutions party thereto. 

“Credit Facilities” means, one or more debt facilities, commercial paper facilities, or capital markets financings, in
each case with banks, investment banks, other institutional lenders or investors or trustees providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose
entities formed to borrow from such lenders against such receivables), letters of credit, or capital markets financings, in each case, as amended, restated, modified, renewed, refunded, replaced or refinanced in whole or in part from time to time.

  
 -7-

 “Default” means any event that is, or with the passage of time or the
giving of notice or both would be, an Event of Default. 
 “Depositary” means, with respect to the 2021 Notes
issuable or issued in whole or in part in global form, the Person specified in Section 2.05 hereof as the Depositary with respect to the 2021 Notes, and any and all successors thereto appointed as depositary hereunder and having become such
pursuant to the applicable provisions of the Base Indenture and this Supplemental Indenture. 
 “Designated
Non-Guarantors” means those certain Domestic Subsidiaries that have been designated by the Company in an Officers’ Certificate delivered to the Trustee as being Designated Non-Guarantors; provided that (i) in no event may
the Designated Non-Guarantors taken as a whole hold more than 7.5% of the consolidated assets, or account for more than 5% of the consolidated revenues or Consolidated Cash Flow, of the Company and its Restricted Subsidiaries, calculated at the end
of each fiscal quarter in accordance with GAAP on a trailing four-quarter basis and (ii) in no event may any Restricted Subsidiary be designated as a Designated Non-Guarantor at a time when a default has occurred and is continuing under any
indenture or Credit Facility of the Company or any of its Restricted Subsidiaries. In the event that following any fiscal quarter end, the Restricted Subsidiaries that have been previously designated as Designated Non-Guarantors, when taken as a
whole, account for more than 7.5% of such consolidated assets of such fiscal quarter end or more than 5% of such consolidated revenues or Consolidated Cash Flow during such fiscal quarter, calculated in accordance with GAAP on a trailing
four-quarter basis, then the Company will cause any one or more of such Restricted Subsidiaries to become Guarantors within 45 days of such fiscal quarter end so that the Designated Non-Guarantors will not, when taken as a whole, account for more
than the applicable percentage of any such measures. Notwithstanding the foregoing, Blanco and all Receivables Subsidiaries will be permitted to be Designated Non-Guarantors, and their assets, revenues and Consolidated Cash Flow will be disregarded
for purposes of the financial tests required by this definition. 
 “Disqualified Stock” means, on any date,
any Capital Stock that, by its terms (or by the terms of any security into which it is convertible or for which it is exchangeable, in each case at the option of the holder of the Capital Stock), or upon the happening of any event, matures or is
mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or redeemable at the option of the holder thereof, in whole or in part, on or prior to the date that is 91 days after the latest date on which the 2021 Notes mature.
Notwithstanding the preceding sentence, any Capital Stock that would constitute Disqualified Stock solely because the holders of the Capital Stock have the right to require the Company to repurchase such Capital Stock upon the occurrence of a change
of control will not constitute Disqualified Stock if the terms of such repurchase rights are not more favorable to the holders of such Capital Stock than the covenant set forth in Section 5.04 hereof. 

“Domestic Subsidiary” means any Restricted Subsidiary of the Company that was formed under the laws of the United States
or any state of the United States or the District of Columbia or that guarantees or otherwise provides direct credit support for any Indebtedness of the Company; provided that a Restricted Subsidiary with assets having an aggregate fair
market 

  
 -8-

 
value of less than $100,000 will not be deemed to be a Domestic Subsidiary unless and until it acquires assets having an aggregate fair market value in excess of that amount. 

“Equity Interests” means Capital Stock and all warrants, options or other rights to acquire Capital Stock (but excluding
any debt security that is convertible into, or exchangeable for, Capital Stock) and beneficial interests and trusts created by a Receivables Subsidiary. 
 “Event of Default” has the meaning specified in Section 3.01 hereof. 
 “Fitch” means Fitch Inc., a subsidiary of Fimalac, S.A., and its successors. 
 “GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public
Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect from time to
time. 
 “Global 2021 Note” means a permanent global 2021 Note substantially in the form of Exhibit A attached
hereto that bears the global note legend set forth therein and that has the “Schedule of Exchanges of Interests in the Global Note” attached thereto, and that is deposited with or on behalf of and registered in the name of the Depositary.

 “Guarantee” means a guarantee other than by endorsement of negotiable instruments for collection in the
ordinary course of business, direct or indirect, in any manner including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any part of any Indebtedness.

 “Guarantor” means each of (a) the guarantors listed on the signature pages hereto and (b) any
other Subsidiary that executes a 2021 Note Guarantee in accordance with the provisions of this Supplemental Indenture, and their respective successors and assigns; in the case of (a) and (b), other than such guarantors or Subsidiaries that are
released pursuant to Sections 8.05 hereof. 
 “Hedging Obligations” means, with respect to any specified
Person, the obligations of such Person under 
 (i) interest rate swap agreements, interest rate cap agreements and
interest rate collar agreements and 
 (ii) other agreements or arrangements designed to protect such Person against
fluctuations in interest rates, foreign currency translation and commodity prices. 
 “Indebtedness” means,
with respect to any specified Person, any indebtedness of such Person, whether or not contingent: 
 (a) in respect of borrowed
money; 
 (b) evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements in
respect thereof); 

  
 -9-

 (c) in respect of banker’s acceptances; 

(d) representing Capital Lease Obligations; 
 (e) representing the balance deferred and unpaid of the purchase price of any property, except any such balance that constitutes an accrued expense or trade payable; or 

(f) representing any Hedging Obligations; 
 if and to the extent any of the preceding items (other than letters of credit) would appear as a liability upon a balance sheet of the specified Person prepared in accordance with GAAP. In addition, the
term “Indebtedness” includes all Indebtedness of others secured by a Lien on any asset of the specified Person (whether or not such Indebtedness is assumed by the specified Person) and, to the extent not otherwise included, the Guarantee
by the specified Person of any Indebtedness of any other Person. 
 The amount of any Indebtedness outstanding as of any date will be:

 (a) the accreted value of the Indebtedness, in the case of any Indebtedness issued with original issue discount; and

 (b) the principal amount of the Indebtedness, together with any interest on the Indebtedness that is more than 30 days past
due, in the case of any other Indebtedness. 
 Indebtedness shall not include the obligations of any Person resulting from post-closing payment
adjustments to which the seller may become entitled in connection with the purchase by the Company or any of its Restricted Subsidiaries of any business, to the extent such payment is determined by a final closing financial statement or such payment
depends on the performance of such business after the closing; provided that at the time of closing, the amount of any such payment is not determinable and, to the extent such payment thereafter becomes fixed and determined, the amount is
paid within 60 days thereafter. 
 “Independent Investment Banker” means the Reference Treasury Dealer
appointed by the Trustee after consultation with the Company. 
 “Initial 2021 Notes” means the first
$500,000,000 aggregate principal amount of the 2021 Notes issued under this Supplemental Indenture on the date hereof. 

“Investment” means, with respect to any Person, all direct or indirect investment by such Person in other Persons
(including Affiliates) in the form of loans (including Guarantees or other obligations), advances or capital contributions (excluding commissions, travel, moving and similar advances to officers and employees and loans and advances to customers and
suppliers made in the ordinary course of business), purchases or other acquisitions for consideration of Indebtedness, Equity Interests or other securities, together with all items that are or would be classified as investments on a balance sheet
prepared in accordance with GAAP. 

  
 -10-

 “Investment Grade” means a rating of Baa3 or better by Moody’s (or its
equivalent under any successor rating category of Moody’s); a rating of BBB- or better by S&P (or its equivalent under any successor rating category of S&P); and a rating of BBB- or better by Fitch (or its equivalent under any successor
rating category of Fitch). 
 “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge,
security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease in the nature thereof,
any agreement to give a security interest in and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes) of any jurisdiction; in each case, except in connection with any Qualified
Receivables Transaction. 
 “Moody’s” means Moody’s Investors Service, Inc., a subsidiary of
Moody’s Corporation, and its successors. 
 “Net Income” means, with respect to any specified Person, the
net income (loss) of such Person, determined in accordance with GAAP and before any reduction in respect of preferred stock dividends, excluding, however, (i) any gain (but not loss), together with any related provision for taxes on such gain
(but not loss), realized in connection with (a) any Asset Sale or (b) the disposition of any securities by such Person or any of its Restricted Subsidiaries or the extinguishment of any Indebtedness of such Person or any of its Restricted
Subsidiaries and (ii) any extraordinary gain (but not loss), together with any related provision for taxes on such extraordinary gain (but not loss). 
 “Non-Recourse Debt” means Indebtedness: 
 (a) as to which neither
the Company nor any of its Restricted Subsidiaries (i) provides credit support of any kind (including any undertaking, agreement or instrument that would constitute Indebtedness), (ii) is directly or indirectly liable as a guarantor or
otherwise or (iii) constitutes the lender; 
 (b) no default with respect to which (including any rights that the holders
of the Indebtedness may have to take enforcement action against an Unrestricted Subsidiary) would permit upon notice, lapse of time or both any holder of any other Indebtedness of the Company or any of its Restricted Subsidiaries to declare a
default on such other Indebtedness or cause the payment of the Indebtedness to be accelerated or payable prior to its Stated Maturity; and 
 (c) as to which the lenders have been notified in writing that they will not have any recourse to the stock or assets of the Company or any of its Restricted Subsidiaries. 

“Notice of Default” has the meaning specified in Section 3.01(c) hereof. 

“Obligations” means any principal, interest, penalties, fees, indemnifications, reimbursements, damages and other
liabilities payable under the documentation governing any Indebtedness. 

  
 -11-

 “Officer” means, with respect to any Person, such Person’s Chairman,
Chief Executive Officer, President, Chief Operating Officer, Chief Financial Officer, Treasurer, any Assistant Treasurer, Controller, Secretary or any Vice President of such Person. 

“Officers’ Certificate” means a certificate signed by any two of any Person’s Chairman, Chief Executive
Officer, Chief Financial Officer, President, Executive Vice President, Senior Vice President, Controller, Treasurer, and any Assistant Treasurer, or by any other officer or officers of such Person pursuant to an applicable Board Resolution, and
delivered to the Trustee. 
 “Payment Default” has the meaning specified in Section 3.01(f) hereof.

 “Permitted Liens” means any of the following: 

(a) Liens securing Indebtedness under Credit Facilities or any Hedging Obligations related thereto, provided, that the foregoing
Liens shall constitute Permitted Liens only to the extent that such Liens secure Indebtedness in an aggregate principal amount outstanding not to exceed, at the time of determination, 15% of the Company’s Consolidated Net Worth; 

(b) Liens on property of a Person existing at the time such Person is merged with or into or consolidated with or acquired by the Company
or any Restricted Subsidiary of the Company; provided that such Liens were in existence prior to the contemplation of such merger or consolidation or acquisition and do not extend to any assets other than those of the Person merged into or
consolidated with the Company or the Restricted Subsidiary; 
 (c) Liens on property existing at the time of acquisition of the
property by the Company or any Restricted Subsidiary of the Company, provided that such Liens were in existence prior to the contemplation of such acquisition; 
 (d) Liens to secure the performance of statutory obligations, surety or appeal bonds, bid bonds, payment bonds, performance bonds or other obligations of a like nature incurred in the ordinary course of
business; 
 (e) Liens existing on the issue date of the 2021 Notes; 

(f) Liens in favor of the Company or the Restricted Subsidiaries; 

(g) Liens for taxes, assessments or governmental charges or claims that are not yet delinquent or that are being contested in good faith
by appropriate proceedings promptly instituted and diligently concluded, provided that any reserve or other appropriate provision as is required in conformity with GAAP has been made therefor; 

(h) Liens on assets of the Company or any of its Subsidiaries (including Receivables Subsidiaries) incurred in connection with a
Qualified Receivables Transaction; 
 (i) Liens on assets of Unrestricted Subsidiaries that secure Non-Recourse Debt of
Unrestricted Subsidiaries; 

  
 -12-

 (j) Liens to secure Indebtedness of a Restricted Subsidiary to the Company or another of its
Restricted Subsidiaries; 
 (k) Liens on any property or asset acquired by the Company or any of its Restricted Subsidiaries in
favor of the seller of such property or asset and construction mortgages on real property, in each case, created within twelve months after the date of acquisition, construction or improvement of such property or asset by the Company or such
Restricted Subsidiary to secure the purchase price or other obligation of the Company or such Restricted Subsidiary to the seller of such property or asset or the construction or improvement cost of such property in an amount up to the total cost of
the acquisition, construction or improvement of such property or asset; provided that in each case, such Lien does not extend to any other property or asset of the Company and its Restricted Subsidiaries; 

(l) Liens incurred or pledges and deposits made in connection with workers’ compensation, unemployment insurance and other social
security benefits; 
 (m) Liens imposed by law, such as mechanics’, carriers’, warehousemen’s,
materialmen’s, and vendors’ Liens, incurred in good faith in the ordinary course of business with respect to amounts not yet delinquent or being contested in good faith by appropriate proceedings if a reserve or other appropriate
provisions, if any, as shall be required by GAAP shall have been made therefor; 
 (n) financing statements granted with respect
to personal property leased by the Company and its Restricted Subsidiaries pursuant to leases considered operating leases in accordance with GAAP, provided that such financing statements are granted solely in connection with such leases; and
Liens to secure Capital Lease Obligations in an amount not to exceed the greater of (x) $125.0 million and (y) 3.0% of the Company’s Consolidated Net Worth covering only the assets acquired with such Indebtedness; 

(o) judgment Liens to the extent that such judgments do not cause or constitute a Default or an Event of Default; 

(p) Liens consisting of easements, rights-of-way, zoning restrictions, restrictions on the use of real property, and defects and
irregularities in the title thereto, landlords’ Liens and other similar Liens and encumbrances none of which interfere materially with the use of the property covered thereby in the ordinary course of the business of the Company or such
Restricted Subsidiary and which do not, in the opinion of the Company, materially detract from the value of such properties; 

(q) Liens in favor of the United States of America or any state thereof, or any department or agency or instrumentality or political
subdivision of the United States of America or any state thereof or political entity affiliated therewith, or in favor of any other country, or any political subdivision thereof, to secure, progress, advance or other payments, or other obligations,
pursuant to any contract or statute, or to secure any Indebtedness incurred for the purpose of financing all or any part of the cost of acquiring, constructing or improving the property subject

  
 -13-

 
to such Liens (including Liens incurred in connection with pollution control, industrial revenue or similar financings); 
 (r) Liens securing Permitted Refinancing Indebtedness incurred to refinance Indebtedness that was secured by a Lien permitted under this Supplemental Indenture; provided that any such Lien shall
not extend to or cover any assets or property not securing the Indebtedness so refinanced and that such refinancing does not, directly or indirectly, result in an increase in the aggregate amount of secured Indebtedness of the Company and its
Restricted Subsidiaries (except to the extent as a result of the financing of accrued interest on the Indebtedness refinanced and the amount of all expenses and premiums incurred in connection with such refinancing); 

(s) any extension or renewal, or successive extensions or renewals, in whole or in part, of Liens permitted pursuant to the foregoing
clauses (a) through (r) provided that no such extension or renewal Lien shall (A) secure more than the amount of Indebtedness or other obligations secured by the Lien being so extended or renewed or (B) extend to any
property or assets not subject to the Lien being so extended or renewed; and 
 (t) Liens incurred in the ordinary course of
business of the Company and its Restricted Subsidiaries with respect to obligations outstanding at any one time that do not exceed the greater of (i) $50.0 million and (ii) 1.0% of the Company’s Consolidated Net Worth. 

“Permitted Refinancing Indebtedness” means any Indebtedness of the Company or any of its Restricted Subsidiaries issued
in exchange for, or the net proceeds of which are used to extend, refinance, renew, replace, defease or refund other Indebtedness of the Company or any of its Restricted Subsidiaries (other than intercompany Indebtedness). 

“Person” means any individual, corporation, partnership, joint venture, association, joint-stock company, trust,
unincorporated organization, limited liability company or government or other entity. 
 “Qualified Receivables
Transaction” means any transaction or series of transactions entered into by the Company or any of its Subsidiaries pursuant to which the Company or any of its Subsidiaries sells, conveys or otherwise transfers to (i) a Receivables
Subsidiary (in the case of a transfer by the Company or any of its Subsidiaries) and (ii) any other Person (in the case of a transfer by a Receivables Subsidiary), or grants a security interest in, any accounts receivable (whether now existing
or arising in the future) or inventory of the Company or any of its Subsidiaries, and any assets related thereto including, without limitation, all collateral securing such accounts receivable, all contracts and all guarantees or other obligations
in respect of such accounts receivable or inventory, proceeds of such accounts receivable and other assets which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization
transactions involving accounts receivable or inventory. 
 “Rating Agency” means each of Moody’s, S&P
and Fitch; provided, that if any of Moody’s, S&P and Fitch ceases to provide rating services to issuers or investors, the Company may appoint a replacement for such Rating Agency that is reasonably acceptable to the Trustee.

  
 -14-

 “Receivables Subsidiary” means a Subsidiary of the Company which engages in
no activities other than in connection with the financing of accounts receivable or inventory and which is designated by the Board of Directors of the Company (as provided below) as a Receivables Subsidiary (a) no portion of the Indebtedness or
any other Obligations (contingent or otherwise) of which (i) is guaranteed by the Company or any Subsidiary of the Company (excluding guarantees of Obligations (other than the principal of, and interest on, Indebtedness) pursuant to
representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction), (ii) is recourse to or obligates the Company or any Subsidiary of the Company in any
way other than pursuant to representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction or (iii) subjects any property or asset of the Company or
any Subsidiary of the Company (other than accounts receivable or inventory and related assets as provided in the definition of “Qualified Receivables Transaction”), directly or indirectly, contingently or otherwise, to the satisfaction
thereof, other than pursuant to representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction, (b) with which neither the Company nor any Subsidiary
of the Company has any material contract, agreement, arrangement or understanding other than on terms customary for securitization of receivables or inventory and (c) with which neither the Company nor any Subsidiary of the Company has any
obligation to maintain or preserve such Subsidiary’s financial condition or cause such Subsidiary to achieve certain levels of operating results. Any such designation by the Board of Directors of the Company will be evidenced to the Trustee by
filing with the Trustee a certified copy of the resolution of the Board of Directors of the Company giving effect to such designation and an Officers’ Certificate certifying that such designation complied with the foregoing conditions.

 “Reference Treasury Dealer” means each of J.P. Morgan Securities LLC, Merrill Lynch, Pierce,
Fenner & Smith Incorporated and one other primary U.S. Government securities dealer in New York City (each, a “Primary Treasury Dealer”) appointed by the Trustee after consultation with the Company and its successors;
provided, however, that if J.P. Morgan Securities LLC or Merrill Lynch, Pierce, Fenner & Smith Incorporated shall cease to be a Primary Treasury Dealer, the Company shall substitute therefor another Primary Treasury Dealer.

 “Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any
Redemption Date, the average as determined by the Trustee, of the bid and asked prices of the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Trustee by such Reference Treasury
Dealer at 5:00 p.m. on the third Business Day preceding such Redemption Date (or, in the case of either legal defeasance or covenant defeasance prior to a Redemption Date, for the applicable date of deposit with the Trustee of funds to pay the
Redemption Price). 
 “Remaining Scheduled Payments” means, with respect to any of the 2021 Notes to be
redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related Redemption Date but for such redemption; provided, however, that, if such Redemption Date is not an Interest
Payment Date with respect to such 2021 Notes, 

  
 -15-

 
the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such Redemption Date. 

“Restricted Subsidiary” of a Person means any Subsidiary of the referent Person that is not an Unrestricted Subsidiary.

 “S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies,
Inc., and its successors. 
 “Securities Act” means the Securities Act of 1933, as amended from time to time,
and any statute successor thereto. 
 “Significant Subsidiary” means any Restricted Subsidiary that would be a
“significant subsidiary” as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as such Regulation is in effect on the date of the Supplemental Indenture. 

“Specified Indebtedness” means (i) any Indebtedness under the Credit Agreement and any Indebtedness incurred under
Credit Facilities that refinances such Indebtedness or (ii) any Trigger Indebtedness. 
 “Stated Maturity”
means, with respect to any installment of interest or principal on any series of Indebtedness, the date on which the payment of interest or principal was scheduled to be paid in the original documentation governing such Indebtedness, and will not
include any contingent obligations to repay, redeem or repurchase any such interest or principal prior to the date originally scheduled for the payment thereof. 
 “Subsidiary” means, with respect to any specified Person: 
 (a)
any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or
trustees of the corporation, association or other business entity is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and 

(b) any partnership (i) the sole general partner or the managing general partner of which is such Person or a Subsidiary of such
Person or (ii) the only general partners of which are that Person or one or more Subsidiaries of that Person (or any combination thereof). 
 “Supplemental Indenture” means this Second Supplemental Indenture, dated as of the date hereof, by and among the Company, the Guarantors and the Trustee, governing the 2021 Notes, as
amended, supplemented or otherwise modified from time to time in accordance with the Base Indenture and the terms hereof. 

“Trigger Indebtedness” means any Indebtedness other than (i) Capital Lease Obligations and (ii) Indebtedness
(other than Capital Lease Obligations) in an aggregate principal amount for all Domestic Subsidiaries of the Company (other than Blanco and any 

  
 -16-

 
Receivables Subsidiary) that are not Guarantors at any time outstanding not to exceed $25 million (the “Original Definition”), provided, however, that for so long as the
Domestic Subsidiaries of the Company (other than Blanco and any Receivables Subsidiary) that are not Guarantors have as a group in excess of $25 million in aggregate principal amount of Indebtedness (other than Capital Lease Obligations)
outstanding, the term Trigger Indebtedness shall mean any Indebtedness; provided further, that from and after any subsequent date that the Domestic Subsidiaries of the Company (other than Blanco and any Receivables Subsidiary) that are not
Guarantors do not have as a group in excess of $25 million in aggregate principal amount of Indebtedness (other than Capital Lease Obligations) outstanding, the term Trigger Indebtedness shall mean the Original Definition. 

“Unrestricted Subsidiary” means any Subsidiary of the Company that is designated by the Board of Directors of the
Company as an Unrestricted Subsidiary pursuant to a Board Resolution, but only to the extent that such Subsidiary: 
 (a) has no
Indebtedness other than Non-Recourse Debt; 
 (b) is not party to any agreement, contract, arrangement or understanding with the
Company or any Restricted Subsidiary of the Company unless the terms of any such agreement, contract, arrangement or understanding are no less favorable to the Company or such Restricted Subsidiary than those that might be obtained at the time from
Persons who are not Affiliates of the Company; 
 (c) is a Person with respect to which neither the Company nor any of its
Restricted Subsidiaries has any direct or indirect obligation (i) to subscribe for additional Equity Interests or (ii) to maintain or preserve such Person’s financial condition or to cause such Person to achieve any specified levels
of operating results; 
 (d) is not guaranteeing or otherwise providing credit support for any Indebtedness of the Company or
any of its Restricted Subsidiaries; and 
 (e) has at least one director on its Board of Directors that is not a director or
executive officer of the Company or any of its Restricted Subsidiaries and has at least one executive officer that is not a director or executive officer of the Company or any of its Restricted Subsidiaries. 

Any designation of a Subsidiary of the Company as an Unrestricted Subsidiary will be evidenced to the Trustee by filing with the Trustee
a certified copy of the Board Resolution giving effect to such designation and an Officers’ Certificate certifying that such designation complied with the preceding conditions. If, at any time, any Unrestricted Subsidiary would fail to meet the
preceding requirements as an Unrestricted Subsidiary, it will thereafter cease to be an Unrestricted Subsidiary for purposes of this Supplemental Indenture and any Indebtedness of such Subsidiary will be deemed to be incurred by a Restricted
Subsidiary of the Company as of such date. The Board of Directors of the Company may at any time designate any Unrestricted Subsidiary to be a Restricted Subsidiary; provided that such designation will be deemed to be an incurrence of
Indebtedness by a Restricted Subsidiary of the Company of any outstanding Indebtedness of such Unrestricted Subsidiary and such designation will only be permitted if (i) 

  
 -17-

 
such Indebtedness is permitted under this Supplemental Indenture and (ii) no Event of Default would be in existence following such designation. Notwithstanding the foregoing, Blanco and all
Receivables Subsidiaries will be permitted to be Unrestricted Subsidiaries. 
 “Voting Stock” of any Person as
of any date means the Capital Stock of such Person that is at the time entitled to vote or readily convertible into Capital Stock of such Person that is entitled to vote in the election of the Board of Directors of such Person. 

Section 1.02. Notices, etc., to Trustee and Company. Any request, order, authorization, direction,
consent, waiver, or other action to be taken by the Trustee, the Company, any Guarantor or the Holders hereunder (including any Authentication Order), and any notice to be given to the Trustee, the Company or any Guarantors with respect to any
action taken or to be taken by the Trustee, the Company, any Guarantor or the Holders hereunder, shall be sufficient if made in writing and delivered electronically or mailed by registered first-class mail postage pre-paid, return receipt requested,
to the following addresses: 
 If to the Trustee: 
 U.S. Bank National Association 
 50 South 16th Street, Suite 2000 

Mail Station EX-PA-WBSP 
 Philadelphia, PA 19102 
 Attention: George J. Rayzis 

Telephone No: (215) 761-9317 
 Facsimile No: (215) 761-9412 
 If to the Company and/or any Guarantor: 

AmerisourceBergen Corporation 
 1300 Morris Drive 
 Chesterbrook, PA 19087 

Attention: Vice President and Treasurer 
 Telephone No: (610) 727-7000 
 Facsimile No: (610) 727-3600 

With a copy to: 
 Morgan,
Lewis & Bockius LLP 
 1701 Market Street 
 Philadelphia, PA 19103 
 Attention: James W. McKenzie, Jr., Esq. 

Telephone No: (215) 963-5000 
 Facsimile No: (215) 963-5001 
 Section 1.03. Conflict with
Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with another provision hereof which is required to be included in this Supplemental Indenture by any of the provisions of the TIA, such required provision
shall control. 

  
 -18-

 Section 1.04. Effect of Headings and Table of Contents. The
Article and Section headings herein and the Table of Contents hereof are for convenience only and shall not affect the construction of any provision of this Supplemental Indenture. 

Section 1.05. Successors and Assigns. All covenants and agreements in this Supplemental Indenture by the
Company or by the Guarantors shall bind their successors and assigns, whether so expressed or not. 

Section 1.06. Severability Clause. In case any provision in this Supplemental Indenture, the 2021 Notes
or the 2021 Note Guarantees shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 1.07. Benefits Of Indenture. Nothing in this Supplemental Indenture, the 2021 Notes or the 2021
Note Guarantees, express or implied, shall give to any Person, other than the parties hereto, their successors hereunder, the Authenticating Agent, the Security Registrar, any Paying Agent, and the Holders (or such of them as may be affected
thereby), any benefit or any legal or equitable right, remedy or claim under this Supplemental Indenture. 

Section 1.08. Governing Law. This Supplemental Indenture, the 2021 Notes and the 2021 Note Guarantees
shall be governed by and construed in accordance with the laws of the State of New York. 
 Section 1.09.
Counterparts. This Supplemental Indenture may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which shall together constitute but one and the same instrument.

 Section 1.10. Immunity of Incorporators, Stockholders, Directors and Officers. No recourse shall be
had for the payment of the principal of, premium, if any, or the interest, if any, on the 2021 Notes or the 2021 Note Guarantees, or for any claim based thereon, or upon any obligation, covenant or agreement of this Supplemental Indenture, the 2021
Notes or the 2021 Note Guarantees against any incorporator, stockholder, member, partner, director, manager, officer or employee, as such, past, present or future, of the Company, any Guarantor or of any successor corporation to the Company or such
Guarantor, either directly or indirectly through the Company, such Guarantor or any successor corporation to the Company or such Guarantor, whether by virtue of any constitution, statute or rule of law or by the enforcement of any assessment of
penalty or otherwise; it being expressly agreed and understood that this Supplemental Indenture and all of the 2021 Notes and the 2021 Note Guarantees are solely corporate obligations, and that no personal liability whatever shall attach to, or is
incurred by, any incorporator, stockholder, member, partner, director, manager, officer or employee, past, present or future, of the Company or any Guarantor or of any successor corporation to the Company or such Guarantor, either directly or
indirectly through the Company, such Guarantor or any successor corporation to the Company or such Guarantor, because of the incurring of any Indebtedness hereby authorized or under or by reason of any of the obligations, covenants or agreements
contained in this Supplemental Indenture or in any of the 2021 Notes or the 2021 Note Guarantees, or to be implied herefrom or therefrom; and that all such personal liability is hereby expressly released and waived as a condition of, and as part of
the consideration for, the 

  
 -19-

 
execution of this Supplemental Indenture and the issuance of the 2021 Notes and the 2021 Note Guarantees. 
 Section 1.11. Qualification of Indenture. The Company shall qualify Base Indenture, as amended and supplemented by this Supplemental Indenture, under the Trust Indenture Act.

 Section 1.12. Relationship with Base Indenture. The terms and provisions contained in this
Supplemental Indenture will constitute, and are hereby expressly made, a part of the Base Indenture and the Company, the Guarantors and the Trustee, by their execution and delivery of this Supplemental Indenture, expressly agree to such terms and
provisions and to be bound thereby; provided, however, that the provisions of this Supplemental Indenture shall apply solely with respect to the 2021 Notes and the 2021 Note Guarantees only and that, except as expressly supplemented hereby
with respect to the 2021 Notes and 2021 Note Guarantees, the Base Indenture shall continue in full force and effect and is in all respects confirmed, ratified and preserved. To the extent any provision of the Base Indenture conflicts with the
express provisions of this Supplemental Indenture, the provisions of this Supplemental Indenture will govern and be controlling with respect to the 2021 Notes and the 2021 Note Guarantees. 

By execution of this Supplemental Indenture, the Trustee accepts the modification of the Base Indenture effected hereby with respect to
the 2021 Notes and the 2021 Note Guarantees only, and agrees to execute the trust created by the Base Indenture as supplemented hereby. 
 Notwithstanding anything contained in this Supplemental Indenture or the Base Indenture to the contrary, this Supplemental Indenture shall not be deemed to amend or modify the Base Indenture with respect
to any series of Securities that may be issued under the Base Indenture other than the 2021 Notes and the 2021 Note Guarantees. 

ARTICLE 2 

The 2021 Notes 
 There is
hereby authorized the following new series of Securities: 
 Section 2.01. Form of 2021 Note and Dating.
 
 (a) The 2021 Notes and the Trustee’s certificate of authentication shall be substantially in the form of
Exhibit A hereto. The 2021 Notes may have notations, legends or endorsements required by law, stock exchange rule or usage. 

(b) The 2021 Notes shall be dated the date of their authentication. 

Section 2.02. Designation and Principal Terms. 

(a) The 2021 Notes and related 2021 Note Guarantees are hereby authorized and designated as the “3.500% Senior Notes due 2021.”

 (b) The 2021 Notes shall be in an aggregate principal amount of $500,000,000, shall bear interest at a rate of
3.500% per annum, shall have a Scheduled Maturity Date of November 15, 2021 and are subject to optional redemption, in whole or in part, at any time prior to the 

  
 -20-

 
Scheduled Maturity Date pursuant to the terms set forth in Article 7 hereof. The 2021 Notes shall be denominated in U.S. dollars. 

(c) The date from which interest shall accrue on the 2021 Notes, the Interest Payment Dates of the 2021 Notes, the Record Date with
respect to each payment of interest on the 2021 Notes and all other terms of the 2021 Notes are set forth in the form of 2021 Note attached hereto as Exhibit A. 
 (d) The 2021 Notes shall be redeemable at the option of the Company as set forth in Article 7 hereof. Subject to Section 5.04 hereof, the 2021 Notes shall not be redeemable at the option of the
Holders. 
 (e) The 2021 Notes shall not be entitled to the benefit of any sinking fund. 

(f) The 2021 Notes shall be unsecured Senior Indebtedness of the Company and shall rank equally with all of the Company’s other
unsecured Senior Indebtedness outstanding from time to time. 
 (g) The terms and provisions contained in the 2021 Notes shall
constitute, and are hereby expressly made, a part of this Supplemental Indenture and the Company, the Guarantors and the Trustee, by their execution and delivery of this Supplemental Indenture, expressly agree to such terms and provisions and to be
bound thereby. However, to the extent any provision of the 2021 Notes conflicts with the express provisions of this Supplemental Indenture, the provisions of this Supplemental Indenture shall govern and be controlling. 

Section 2.03. Denominations. The 2021 Notes shall be issuable only in registered form, without interest
coupons, in minimum denominations of $2,000 and any integral multiples of $1,000. 
 Section 2.04. Global
Form. The 2021 Notes shall be issued in global form substantially in the form of Exhibit A attached hereto (including the legend thereon and the “Schedule of Exchanges of Interests in the Global Note” attached thereto). Each Global
2021 Note shall represent such of the 2021 Notes then Outstanding as shall be specified therein and each shall provide that it shall represent the aggregate principal amount of the 2021 Notes of the applicable series then Outstanding from time to
time endorsed thereon and that the aggregate principal amount of the 2021 Notes of the applicable series then Outstanding represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and redemptions. Any
endorsement of a Global 2021 Note to reflect the amount of any increase or decrease in the aggregate principal amount of the 2021 Notes of the applicable series then Outstanding represented thereby shall be made by the Trustee, in accordance with
instructions given by the Holder thereof as required by Section 3.05 of the Base Indenture. 
 Section 2.05.
Depositary. The Company initially appoints The Depository Trust Company (“DTC”) to act as Depositary with respect to the Global 2021 Notes. 
 Section 2.06. Execution, Authentication and Delivery, and Dating. The 2021 Notes shall be executed on behalf of the Company by any two of its Officers under its corporate
seal reproduced thereon and attested by its Secretary or any one of its Assistant Secretaries. Pursuant 

  
 -21-

 
to Section 8.03 hereof, each 2021 Note Guarantee shall be executed on behalf of the applicable Guarantor by its President or one of its Vice Presidents. The signature of any of these
officers on the 2021 Notes and the 2021 Note Guarantees may be manual or facsimile. The seal of the Company may be in the form of a facsimile thereof and may be impressed, affixed, imprinted, or otherwise reproduced on the 2021 Notes. Typographical
and other minor errors or defects in any such reproduction of the seal or any such signature shall not affect the validity or enforceability of the 2021 Notes that have been duly authenticated and delivered by the Trustee. 

Unless otherwise provided in the 2021 Notes or the 2021 Note Guarantees, all of the 2021 Notes and the 2021 Note Guarantees shall be
dated the date of their authentication. 
 Any of the 2021 Notes or the 2021 Note Guarantees bearing the manual or facsimile
signatures of individuals who were at any time the proper officers of the Company or any Guarantor shall bind the Company and such Guarantor, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the
authentication and delivery of such 2021 Notes and 2021 Note Guarantees or did not hold such offices at the date of such 2021 Notes and 2021 Note Guarantees. 
 At any time and from time to time after the execution and delivery of this Supplemental Indenture, the Company may deliver the 2021 Notes and the 2021 Note Guarantees to the Trustee for authentication,
together with an Authentication Order with respect to such 2021 Notes and 2021 Note Guarantees, and the Trustee shall, upon receipt of such Authentication Order, in accordance with procedures acceptable to the Trustee set forth in the Authentication
Order, and subject to the provisions hereof and of the Base Indenture, authenticate and deliver such 2021 Notes and 2021 Note Guarantees to such recipients as may be specified from time to time pursuant to such Authentication Order. The material
terms of such 2021 Notes and 2021 Note Guarantees shall be determinable by reference to such Authentication Order and procedures. If provided for in such procedures, such Authentication Order may authorize authentication and delivery of such 2021
Notes and 2021 Note Guarantees pursuant to oral instructions from the Company, any Guarantor or any duly authorized agent of the Company or such Guarantor, which instructions shall be promptly confirmed in writing. In authenticating such 2021 Notes
and 2021 Note Guarantees and accepting the additional responsibilities under this Supplemental Indenture in relation to such 2021 Notes and 2021 Note Guarantees, the Trustee shall be entitled to receive, and (subject to the provisions of
Section 6.05 of the Base Indenture) shall be fully protected in relying upon: 
 (1) an Officers’ Certificate,
certifying as to the authorized forms and terms of the 2021 Notes and the 2021 Note Guarantees; and 
 (2) an Opinion of
Counsel, stating that: 
 (a) the forms and terms of such 2021 Notes and 2021 Note Guarantees have been established by and in
conformity with the provisions of the Base Indenture and this Supplemental Indenture; provided that if all such 2021 Notes and 2021 Note Guarantees are not to be issued at the same time, such Opinion of Counsel may state that such terms will
be established in conformity with the provisions of the Base Indenture and this Supplemental Indenture, subject to any conditions specified in such Opinion of Counsel; and 

  
 -22-

 (b) such 2021 Notes and 2021 Note Guarantees, when authenticated and delivered by the
Trustee and issued by the Company in the manner and subject to any conditions specified in such Opinion of Counsel, will constitute valid and legally binding obligations of the Company and the Guarantors, enforceable in accordance with their terms,
subject to bankruptcy, insolvency, moratorium, reorganization, and other laws of general applicability relating to or affecting the enforcement of creditors’ rights and to general principles of equity; 

provided, however, that if all of the 2021 Notes and the 2021 Note Guarantees issuable by or pursuant to a Board Resolution of the Company are not
to be originally issued at one time, it shall not be necessary to deliver the Officers’ Certificate or Opinion of Counsel otherwise required pursuant to this paragraph at or prior to the time of authentication of such 2021 Notes or 2021 Note
Guarantees if such documents are delivered at or prior to the time of authentication upon original issuance of such 2021 Notes or 2021 Note Guarantees to be issued. After the original issuance of such 2021 Notes or 2021 Note Guarantees to be issued,
any separate request by the Company that the Trustee authenticate such 2021 Notes or 2021 Note Guarantees for original issuance will be deemed to be a certification by the Company that it is in compliance with all conditions precedent provided for
in the Base Indenture and this Supplemental Indenture relating to the authentication and delivery of such 2021 Notes and 2021 Note Guarantees. 
 None of the 2021 Notes or the 2021 Note Guarantees shall be entitled to any benefit under the Base Indenture or this Supplemental Indenture or be valid or obligatory for any purpose unless there appears
on such 2021 Notes or 2021 Note Guarantees a certificate of authentication executed by the Trustee by manual signature of an authorized signatory, and such certificate upon any of the 2021 Notes or the 2021 Note Guarantees shall be conclusive
evidence, and the only evidence, that such 2021 Notes or 2021 Note Guarantees have been duly authenticated and delivered hereunder. 
 Section 2.07. CUSIP Number. The Company in issuing the 2021 Notes may use Committee on Uniform Security Identification Procedures (“CUSIP”) numbers (if then generally
in use), and, if so, the Trustee will use CUSIP numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on
the 2021 Notes or as contained in any notice of a redemption and that reliance may be placed only on the other identification numbers printed on the 2021 Notes, and any such redemption will not be affected by any defect in or the omission of such
numbers. The Company will promptly notify the Trustee in writing of any change in the CUSIP numbers. 

Section 2.08. Issuance of Additional 2021 Notes. The Company will be entitled, upon delivery of an
Officer’s Certificate and an Opinion of Counsel to issue Additional 2021 Notes under this Supplemental Indenture which will have identical terms as the Initial 2021 Notes issued on the date hereof, other than with respect to the date of
issuance and issue price. The Initial 2021 Notes issued on the date hereof and any Additional 2021 Notes issued will be treated as a single class for all purposes under this Supplemental Indenture. With respect to any Additional 2021 Notes, the
Company will set forth in a Board Resolution and an Officer’s Certificate, a copy of each which will be delivered to the Trustee, the following information: 

  
 -23-

 (a) the aggregate principal amount of such Additional 2021 Notes to be authenticated and
delivered pursuant to this Supplemental Indenture; and 
 (b) the issue price, the issue date and the CUSIP number of such
Additional 2021 Notes. 
 ARTICLE 3 
 Remedies 
 Section 3.01. Events of Default.
The definition of “Event of Default” set in the Base Indenture shall be inapplicable to the 2021 Notes and 2021 Note Guarantees. For all purposes under this Supplemental Indenture and with respect to the 2021 Notes and 2021 Note
Guarantees, “Event of Default” shall mean any one of the following events: 
 (a) default in the payment of any
interest on the 2021 Notes when it becomes due and payable, and continuance of such default for a period of 30 days; or 
 (b)
default in the payment of the principal amount of (or premium, if any, on) the 2021 Notes as and when the same shall become due, either at Stated Maturity, upon redemption, by declaration, or otherwise; or 

(c) default, subject to the provisions of Section 10.06 of the Base Indenture, in the performance or breach of any covenant or
warranty of the Company in the Base Indenture or this Supplemental Indenture (other than a covenant or warranty a default in the performance of which or the breach of which is elsewhere in this Section 3.01 specifically dealt with), and
continuance of such default or breach for a period of 90 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the 2021
Notes, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or 
 (d) the entry of an order for relief against the Company or any of its Significant Subsidiaries or any group of its Restricted Subsidiaries that, taken as a whole, would constitute a Significant
Subsidiary, under Bankruptcy Law by a court having jurisdiction in the premises or a decree or order by a court having jurisdiction in the premises adjudging the Company, the Significant Subsidiary or such group of Restricted Subsidiaries a bankrupt
or insolvent under any other applicable Federal or State law, or the entry of a decree or order approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company, or any of its
Significant Subsidiaries or any group of its Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, under Bankruptcy Law or any other applicable Federal or State law, or appointing a receiver, liquidator,
assignee, trustee, sequestrator (or other similar official) of the Company, or any of its Significant Subsidiaries or any group of its Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, or of any substantial
part of their respective property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 90 consecutive days; or 

  
 -24-

 (e) the consent by the Company, or any of its Significant Subsidiaries or any group of its
Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, to the institution of bankruptcy or insolvency proceedings against it, or the filing by them of a petition or answer or consent seeking reorganization or
relief under Bankruptcy Law or any other applicable Federal or State law, or the consent by them to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee, sequestrator (or other similar official) of the
Company, the Significant Subsidiary or such group of Restricted Subsidiaries or of any substantial part of their respective property, or the making by it of an assignment for the benefit of creditors, or the admission by them in writing of their
inability to pay their debts generally as they become due, or the taking of corporate action by the Company, the Significant Subsidiary or such group of Restricted Subsidiaries in furtherance of any such action; 

(f) failure by the Company or any of its Restricted Subsidiaries to comply with Section 5.04, and continuance of such default for a
period of 30 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the 2021 Notes of a Notice of Default; 

(g) default under any mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced any
Indebtedness for money borrowed by the Company or any of its Restricted Subsidiaries (or the payment of which is guaranteed by the Company or any of its Subsidiaries), whether such Indebtedness or Guarantee now exists, or is created after the date
of this Supplemental Indenture, which (i) is caused by the failure to pay principal of, or interest or premium, if any, on such Indebtedness prior to the expiration of the grace period provided in such Indebtedness on the date of such default
(a “Payment Default”), and (ii) results in the actual acceleration of such Indebtedness prior to its express maturity, and, in each case, the principal amount of such Indebtedness, together with the principal amount of any
other such Indebtedness under which there has been a Payment Default or the maturity of which has been so accelerated, aggregates $50.0 million or more; 
 (h) a final judgment or final judgments for the payment of money are entered by a court or courts of competent jurisdiction against the Company or any of its Significant Subsidiaries or any group of
Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary and such judgment or judgments remain undischarged for a period (during which execution shall not be effectively stayed pending appeal (or otherwise stayed)) of 60 days,
provided that the aggregate of all such undischarged judgments exceeds $50.0 million (net of any amount covered by insurance); 
 (i) except as permitted by this Supplemental Indenture, any 2021 Note Guarantee is held in any judicial proceeding to be unenforceable or invalid or shall cease for any reason to be in full force and
effect or any Guarantor, or any Person acting on behalf of any Guarantor, shall deny or disaffirm its obligations under such Guarantor’s 2021 Note Guarantee. 
 Section 3.02. Action by Holders. All references to “51%” in Section 5.02 (Acceleration of Maturity; Rescission, and Amendment) and Section 5.07
(Limitation on Suits) of the Base Indenture shall be replaced with “25%” for purposes of the 2021 Notes. 

  
 -25-

 ARTICLE 4 
 Supplemental Indentures 
 Section 4.01. Supplemental
Indentures Without Consent of Securityholders. Without the consent of the Holders of the 2021 Notes, the Company, the Guarantors and the Trustee, at any time and from time to time, may enter into one or more indentures supplemental
hereto (which shall conform to the provisions of the TIA as in force at the date of execution thereof), in form satisfactory to the Trustee, for any of the following purposes: 
 (a) to evidence the succession of another corporation to the Company or any Guarantor, or successive successions, and the assumption by any such successor of the covenants, agreements and obligations of
the Company and such Guarantor pursuant to Article 6 and Section 8.04 hereof; or 
 (b) to add to the covenants of the
Company such further covenants, restrictions or conditions for the protection of the Holders of the 2021 Notes as the Company and the Trustee shall consider to be for the protection of the Holders of the 2021 Notes or to surrender any right or power
herein conferred upon the Company; or 
 (c) to cure any ambiguity, to correct or supplement any provision herein which may be
inconsistent with any other provision herein or in any supplemental indenture hereto, or to make any other provisions with respect to matters or questions arising under this Supplemental Indenture that do not adversely affect the interests of the
Holders of the 2021 Notes in any material respect; or 
 (d) to add to this Supplemental Indenture such provisions as may be
expressly permitted by the TIA, excluding, however, the provisions referred to in Section 316(a)(2) of the TIA as in effect at the date as of which this instrument is executed or any corresponding provision in any similar federal statute
hereafter enacted; or 
 (e) to add guarantors or co-obligors with respect to the 2021 Notes; or 

(f) to secure the 2021 Notes; or 
 (g) to add to the rights of the Holders of the 2021 Notes; or 
 (h) to evidence
and provide for the acceptance of appointment by another corporation as a successor Trustee hereunder with respect to the 2021 Notes and to add to or change any of the provisions of this Supplemental Indenture as shall be necessary to provide for or
facilitate the administration of the trusts hereunder by more than one Trustee, pursuant to Section 6.11 of the Base Indenture; or 
 (i) to add any additional Events of Default in respect of the 2021 Notes; or 
 (j)
to comply with the requirements of the Commission in connection with the qualification of this Supplemental Indenture under the TIA; 

  
 -26-

 (k) to conform the text of this Supplemental Indenture, the 2021 Notes or the 2021 Note
Guarantees to any provision of the “Description of Notes” section of the Company’s Prospectus Supplement dated November 8, 2011, relating to the initial offering of the 2021 Notes, to the extent that such provision in the
“Description of Notes” was intended to be a verbatim recitation of a provision of this Supplemental Indenture, the 2021 Notes or the Guarantees; or 
 (l) to allow any Guarantor to execute a joinder to this Supplemental Indenture and/or a 2021 Note Guarantee with respect to the 2021 Notes. 

Section 4.02. Supplemental Indentures With Consent of Securityholders. With the consent of the Holders
of not less than a majority in principal amount of the 2021 Notes, by Act of said Holders delivered to the Company and the Trustee, the Company, the Guarantors and the Trustee may from time to time and at any time enter into an indenture or
indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Supplemental Indenture or of any supplemental indenture hereto, of modifying in any manner the rights
of the Holders of the 2021 Notes under this Supplemental Indenture, or of modifying the terms of the 2021 Note Guarantees; provided, however, that no such supplemental indenture shall, without the consent of the Holder of each of the 2021
Notes then Outstanding affected thereby: 
 (a) change the Scheduled Maturity Date or the stated payment date of any payment of
premium or interest payable on any of the 2021 Notes, or reduce the principal amount thereof, or any amount of interest or premium payable thereon, or 
 (b) change the method of computing the amount of principal of any of the 2021 Notes or any interest payable thereon on any date, or change any Place of Payment where, or the coin or currency in which, any
of the 2021 Notes or any payment of premium or interest thereon is payable, or 
 (c) impair the right to institute suit for the
enforcement of any payment described in clauses (a) or (b) on or after the same shall become due and payable, whether at Stated Maturity or, in the case of redemption or repayment, on or after the Redemption Date or the Change of Control
Repayment Date, as the case may be; or 
 (d) change or waive the redemption or repayment provisions of the 2021 Notes;

 (e) reduce the percentage in principal amount of the 2021 Notes then Outstanding, the consent of whose Holders is required
for any such supplemental indenture, or the consent of whose Holders is required for any waiver of compliance with certain provisions of this Supplemental Indenture or certain defaults hereunder and their consequences, provided for in this
Supplemental Indenture; or 
 (f) modify any of the provisions of this Section or Sections 5.13 or 10.06 of the Base Indenture,
except to increase any such percentage or to provide that certain other provisions of this Supplemental Indenture cannot be modified or waived without the consent of the Holder of each of the 2021 Notes then Outstanding affected thereby;
provided, however, that this clause shall not be deemed to require the consent of any Holder with respect to changes in the 

  
 -27-

 
references to “the Trustee” and concomitant changes in this Section and Section 10.06 of the Base Indenture, or the deletion of this proviso, in accordance with the requirements of
Sections 6.11 and 9.01(h) of the Base Indenture; or 
 (g) adversely affect the ranking or priority of the 2021 Notes;

 (h) release any Guarantor or co-obligor from any of its Obligations under its 2021 Note Guarantee or this Supplemental
Indenture, except in compliance with the terms of this Supplemental Indenture; or 
 (i) waive any Event of Default pursuant to
Section 3.01(a), Section 3.01(b) or Section 3.01(c) hereof with respect to the 2021 Notes. 
 It shall not be
necessary for any Act of Holders under this Section to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such Act shall approve the substance thereof. 

Section 4.03. Execution of Supplemental Indentures. Upon request of the Company and upon filing with the
Trustee of evidence of an Act of Holders as aforementioned, the Trustee and the Guarantors shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, powers,
trusts, duties or immunities under the Base Indenture and this Supplemental Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture. In executing, or accepting
the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Supplemental Indenture, the Trustee shall be entitled to receive, and (subject to Section 6.01 of
the Base Indenture) shall be fully protected in relying upon, an Opinion of Counsel stating that the execution of such supplemental indenture is authorized or permitted by this Supplemental Indenture. 

Section 4.04. Effect of Supplemental Indentures. Upon the execution of any supplemental indenture under
this Article, this Supplemental Indenture shall be and be deemed to be modified and amended in accordance therewith, and such supplemental indenture shall form a part of this Supplemental Indenture for all purposes; and the respective rights,
limitation of rights, duties, powers, trusts and immunities under this Supplemental Indenture of the Trustee, the Company, the Guarantors and every Holder of the 2021 Notes theretofore or thereafter authenticated and delivered hereunder shall be
determined, exercised and enforced thereunder to the extent provided therein. 
 Section 4.05. Conformity With
Trust Indenture Act. Every supplemental indenture executed pursuant to this Article shall conform to the requirements of the TIA as then in effect. 
 Section 4.06. Reference in 2021 Notes to Supplemental Indentures. The 2021 Notes authenticated and delivered after the execution of any supplemental indenture pursuant to
this Article may, and shall if required by the Trustee, bear a notation in form approved by the Trustee as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities so modified as to conform, in the
opinion of the Trustee and the Company, to any modification of this Supplemental Indenture contained in any such supplemental indenture may 

  
 -28-

 
be prepared and executed by the Company and the Guarantors and authenticated and delivered by the Trustee in exchange for any of the 2021 Notes then Outstanding. 

ARTICLE 5 

Covenants 

In addition to the covenants set forth in Article 10 of the Base Indenture, the following additional covenants shall apply with respect
to the 2021 Notes. 
 Section 5.01. Payment of Principal, Premium and Interest. The Company or
any Guarantor, for the benefit of the 2021 Notes, will duly and punctually pay in U.S. Dollars the principal of, premium, if any, and interest, if any, on the 2021 Notes in accordance with the terms of the 2021 Notes and this Supplemental Indenture.
An installment of principal of, premium or interest on such 2021 Notes shall be considered paid on the date it is due if the Trustee or a Paying Agent for such 2021 Notes (other than the Company or an Affiliate of the Company) holds on that date
immediately available funds designated for and sufficient to pay such installment. 
 Section 5.02. Liens.
The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly, create, incur, assume or suffer to exist any Lien of any kind securing Indebtedness on any asset now owned or hereafter acquired, except
Permitted Liens, unless (a) in the case of the Company, the 2021 Notes are secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien or (b) in the case of any Guarantor, such Guarantor’s 2021
Note Guarantee is secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien. 

Notwithstanding the foregoing, any Lien securing the 2021 Notes or the Note Guarantees pursuant to this covenant shall be automatically
and unconditionally released and discharged upon the release by all holders of the Indebtedness secured by the Lien giving rise to the Lien securing the 2021 Notes or the 2021 Note Guarantees (including any deemed released upon payment in full of
all obligations under such Indebtedness). 
 Section 5.03. Limitation on Sale and Leaseback Transactions.
The Company will not, and will not permit any of its Restricted Subsidiaries to, enter into any sale and leaseback transaction; provided that the Company or any Guarantor may enter into a sale and leaseback transaction if (i) the
Company or such Guarantor, as applicable, could have incurred a Lien to secure such Indebtedness in an amount equal to the Attributable Indebtedness relating to such sale and leaseback transaction pursuant to the provisions of Section 5.02
hereof and (ii) the gross cash proceeds of such sale and leaseback transaction are at least equal to the fair market value (as determined in good faith by the Board of Directors of the Company and set forth in an Officers’ Certificate
delivered to the Trustee) of the property that is the subject of such sale and leaseback transaction. 

Section 5.04. Offer to Repurchase Upon Change of Control. 

(a) Upon the occurrence of a Change of Control Triggering Event, unless the Company has exercised its right to redeem the 2021 Notes as
described in Section 7.01 hereof within 60 days after the Change of Control Triggering Event, each Holder shall have the right to 

  
 -29-

 
require the Company to purchase all or a portion (equal to $1,000 or an integral multiple thereof) of such Holder’s 2021 Notes pursuant to the offer described below (the “Change of
Control Offer”), at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase (the “Change of Control Payment”), subject to the rights of the Holders of
the 2021 Notes on the relevant Record Date to receive interest due on the relevant Interest Payment Date. Within 30 days following the date upon which the Change of Control Triggering Event occurred, or at the Company’s option, prior to any
Change of Control but after public announcement of the pending Change of Control, the Company shall send, by first class mail, a notice to each Holder of the 2021 Notes, with a copy to the Trustee, which notice shall govern the terms of the Change
of Control Offer, describing the transaction or transactions that constitute the Change of Control Triggering Event and stating: 
 (i) that the Change of Control Offer is being made pursuant to this Section 5.04 and that all 2021 Notes tendered will be accepted for payment; 

(ii) the purchase price and the purchase date, which shall be no earlier than 30 Business Days and no later than 60 Business Days from
the date such notice is mailed, other than as may be required by law (the “Change of Control Payment Date”); 

(iii) that any 2021 Note not tendered will continue to accrue interest; 

(iv) that, unless the Company defaults in the payment of the Change of Control Payment, all 2021 Notes accepted for payment pursuant to
the Change of Control Offer shall cease to accrue interest after the Change of Control Payment Date; 
 (v) that Holders
electing to have any 2021 Notes purchased pursuant to a Change of Control Offer will be required to surrender the 2021 Notes, with the form entitled “Option of Holder to Elect Purchase” on the reverse of the 2021 Notes completed, to the
Paying Agent at the address specified in the notice prior to the close of business on the third Business Day preceding the Change of Control Payment Date; 
 (vi) that Holders will be entitled to withdraw their election if the Paying Agent receives, not later than the close of business on the second Business Day preceding the Change of Control Payment Date, a
telegram, telex, facsimile or other electronic transmission or letter setting forth the name of the Holder, the principal amount of 2021 Notes delivered for purchase, and a statement that such Holder is withdrawing his election to have the 2021
Notes purchased; and 
 (vii) that Holders whose 2021 Notes are being purchased only in part will be issued new 2021 Notes equal
in principal amount to the unpurchased portion of the 2021 Notes surrendered, which unpurchased portion must be equal to $1,000 in principal amount or an integral multiple thereof. 

The Company shall comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations
thereunder to the extent such laws and regulations are applicable in connection with the repurchase of 2021 Notes in connection with a Change of Control Triggering Event. To the extent that the provisions of any securities laws or regulations
conflict with this Section 5.04, the Company will comply with the applicable securities laws and 

  
 -30-

 
regulations and will not be deemed to have breached its obligations under this Section 5.04 by virtue of such conflict. 

(b) On the Change of Control Payment Date, the Company shall, to the extent lawful, (i) accept for payment all 2021 Notes or
portions thereof properly tendered pursuant to the Change of Control Offer, (ii) deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all 2021 Notes or portions thereof properly tendered and
(iii) deliver or cause to be delivered to the Trustee (by book entry) the 2021 Notes properly accepted together with an Officers’ Certificate stating the aggregate principal amount of 2021 Notes or portions thereof being purchased by the
Company. The Paying Agent shall promptly mail to each Holder of 2021 Notes properly tendered the Change of Control Payment for such 2021 Notes, and the Trustee shall promptly cause to be transferred by book entry to each Holder an interest in the
2021 Notes equal in principal amount to any unpurchased portion of the 2021 Notes surrendered by such Holder, if any; provided, that each such 2021 Note shall be in a principal amount of $2,000 or an integral multiple of $1,000 in excess
thereof. The Company shall publicly announce the results of the Change of Control Offer on or as soon as practicable after the Change of Control Payment Date. 
 The Company will not be required to make a Change of Control Offer upon a Change of Control Triggering Event if a third party makes the Change of Control Offer in the manner, at the times and otherwise in
compliance with the requirements set forth in this Section 5.04 and all other provisions of this Supplemental Indenture applicable to a Change of Control Offer made by the Company and purchases all 2021 Notes properly tendered and not withdrawn
under such Change of Control Offer. 
 Section 5.05. Additional 2021 Note Guarantees. Any Domestic
Subsidiary of the Company (other than Blanco or any Receivables Subsidiary) which incurs, has outstanding or guarantees any Specified Indebtedness shall, simultaneously with such incurrence or guarantee (or, if the Domestic Subsidiary has
outstanding or guarantees Specified Indebtedness at the time of its creation or acquisition, at the time of such creation or acquisition) shall become a Guarantor and execute and deliver to the Trustee a 2021 Note Guarantee and a joinder to this
Supplemental Indenture pursuant to which such Subsidiary shall agree to guarantee the Company’s obligations under the 2021 Notes, except for all Subsidiaries that have properly been designated as Unrestricted Subsidiaries or Designated
Non-Guarantors in accordance with this Supplemental Indenture for so long as they continue to constitute Unrestricted Subsidiaries or Designated Non-Guarantors. The form of such 2021 Note Guarantee and such joinder to this Supplemental Indenture is
attached hereto as Exhibit B and Exhibit C, respectively. 
 Section 5.06. Designation of Restricted and
Unrestricted Subsidiaries. The Board of Directors of the Company may designate any Restricted Subsidiary to be an Unrestricted Subsidiary if that designation would not cause a Default. The Board of Directors of the Company may redesignate
any Unrestricted Subsidiary to be a Restricted Subsidiary if the redesignation would not cause a Default. 

Section 5.07. SEC Reports. Whether or not required the Company is required by the rules and regulations of the
Commission, so long as any 2021 Notes are outstanding, the Company will file a copy of: 

  
 -31-

 (i) all quarterly and annual financial information required to be contained in a filing with
the SEC on Forms 10-Q and 10-K; and 
 (ii) all current reports required to be filed with the SEC on Form 8-K;

 with the Commission for public availability within the time periods specified in the Commission’s rules and regulations (unless the
Commission will not accept such a filing) and make such information available to securities analysts and prospective investors upon request. 
 ARTICLE 6 
 Successors 

Section 6.01. Merger, Consolidation or Sale of Assets. The Company shall not, directly or indirectly,
consolidate or merge with or into (whether or not the Company is the surviving corporation), or sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted
Subsidiaries, taken as a whole, in one or more related transactions to, another Person, unless: 
 (a) either the Company is the
surviving corporation or the Person formed by or surviving any such consolidation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition shall have been made is a corporation, limited
liability company or limited partnership organized or existing under the laws of the United States, any state thereof or the District of Columbia and, if such entity is not a corporation, a co-obligor of the 2021 Notes is a corporation organized or
existing under any such laws; 
 (b) the Person formed by or surviving any such consolidation or merger (if other than the
Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition shall have been made assumes all the obligations of the Company under the 2021 Notes and this Supplemental Indenture, and to the extent applicable to
the 2021 Notes, the Base Indenture, pursuant to agreements reasonably satisfactory to the Trustee; 
 (c) immediately after
giving effect to such transaction, no Default or Event of Default shall have happened and be continuing; and 
 (d) the Company
has delivered to the Trustee an Opinion of Counsel as conclusive evidence that any such consolidation, merger, conveyance or transfer and any assumption permitted or required by this Article complies with the provisions of this Article. 

The provisions of this Section 6.01 shall not apply to a sale, merger, assignment, transfer, conveyance or other disposition of assets between or
among the Company and any of its Restricted Subsidiaries. 

  
 -32-

 ARTICLE 7 
 Optional Redemption of 2021 Notes by Company 
 Section 7.01.
Optional Redemption.  
 (a) Except as set forth in Section 7.01(b) hereof, the Company shall have the option
to redeem the 2021 Notes, in whole or in part at any time and from time to time prior to August 15, 2021, at a Redemption Price (expressed as percentage of principal amount) equal to the greater of: 

(i) 100% of the principal amount thereof; or 
 (ii) as determined by an Independent Investment Banker, the sum of the present values of the Remaining Scheduled Payments discounted to the Redemption Date on a semiannual basis (assuming a 360-day year
consisting of twelve 30-day months) at the Adjusted Treasury Rate; 
 in each case, plus accrued and unpaid interest thereon, if any, to the
applicable Redemption Date. 
 (b) On and after August 15, 2021, the Company shall have the option to redeem the 2021
Notes, in whole or in part at any time and from time to time, at a Redemption Price (expressed as percentage of principal amount) equal to 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest thereon, if
any, to the applicable Redemption Date. 
 (c) Unless the Company defaults in payment of the Redemption Price, on and after the
Redemption Date, interest will cease to accrue on the 2021 Notes or portion thereof called for redemption. 
 (d) Any redemption
pursuant to this Section 7.01 shall be made pursuant to the provisions of Section 11.01 through Section 11.07 of the Base Indenture. 
 Section 7.02. Mandatory Redemption. Except as set forth above in Section 5.04 hereof, the Company shall not be required to make mandatory redemption or sinking fund payments
with respect to the 2021 Notes. 
 ARTICLE 8 
 2021 Note Guarantees 
 Section 8.01. Guarantee.
Subject to this Article 8, each of the Guarantors hereby, jointly and severally, unconditionally guarantees to each Holder of the 2021 Notes authenticated and delivered by the Trustee and to the Trustee and its successors and assigns,
irrespective of the validity and enforceability of this Supplemental Indenture, the 2021 Notes and the obligations of the Company hereunder or thereunder, that: 
 (a) the principal of and interest on the 2021 Notes will be promptly paid in full when due, whether at Stated Maturity, by acceleration, redemption, mandatory repurchase or otherwise, and interest on the
overdue principal of and interest on the 2021 Notes, if any, if 

  
 -33-

 
lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder will be promptly paid in full or performed, all in accordance with the terms hereof and
thereof; and 
 (b) in case of any extension of time of payment or renewal of any 2021 Notes or any of such other obligations,
that same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at Stated Maturity, by acceleration, redemption, mandatory repurchase or otherwise. 

Failing payment when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Guarantors shall be
jointly and severally obligated to pay the same immediately. Each Guarantor agrees that this is a Guarantee of payment and not a Guarantee of collection. 
 The Guarantors agree that their obligations hereunder shall be unconditional, irrespective of the validity, regularity or enforceability of the 2021 Notes or this Supplemental Indenture, the absence of
any action to enforce the same, any waiver or consent by any Holder of the 2021 Notes with respect to any provisions hereof or thereof, the recovery of any judgment against the Company, any action to enforce the same or any other circumstance which
might otherwise constitute a legal or equitable discharge or defense of any Guarantor. Each Guarantor waives diligence, presentment, demand of payment, filing of claims with a court in the event of insolvency or bankruptcy of the Company, any right
to require a proceeding first against the Company, protest, notice and all demands whatsoever and covenant that this 2021 Note Guarantee shall not be discharged except by complete performance of the obligations contained in the 2021 Notes and this
Supplemental Indenture. 
 If any Holder or the Trustee is required by any court or otherwise to return to the Company, the
Guarantors or any custodian, trustee, liquidator or other similar official acting in relation to either the Company or the Guarantors, any amount paid by either to the Trustee or such Holder, this 2021 Note Guarantee, to the extent theretofore
discharged, shall be reinstated in full force and effect. 
 Each Guarantor agrees that it shall not be entitled to any right of
subrogation in relation to the Holders in respect of any obligations guaranteed hereby until payment in full of all obligations guaranteed hereby. Each Guarantor further agrees that, as between the Guarantors, on the one hand, and the Holders and
the Trustee, on the other hand, (i) the maturity of the obligations guaranteed hereby may be accelerated as provided in Section 5.02 of the Base Indenture or Section 3.01 hereof for the purposes of this 2021 Note Guarantee,
notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the obligations guaranteed hereby, and (ii) in the event of any declaration of acceleration of such obligations as provided in
Section 5.02 of the Base Indenture or Section 3.01 hereof, such obligations (whether or not due and payable) shall forthwith become due and payable by the Guarantors for the purpose of this 2021 Note Guarantee. The Guarantors shall have
the right to seek contribution from any non-paying Guarantor so long as the exercise of such right does not impair the rights of the Holders under the 2021 Note Guarantee. 

  
 -34-

 Section 8.02. Limitation on Guarantor Liability. Each
Guarantor, and by its acceptance of 2021 Notes, each Holder, hereby confirms that it is the intention of all such parties that the 2021 Note Guarantee of such Guarantor not constitute a fraudulent transfer or conveyance for purposes of Bankruptcy
Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to any 2021 Note Guarantee. To effectuate the foregoing intention, the Trustee, the Holders and the
Guarantors hereby irrevocably agree that the obligations of any Guarantor will, after giving effect to such maximum amount and all other contingent and fixed liabilities of such Guarantor that are relevant under such laws, and after giving effect to
any collections from, rights to receive contribution from or payments made by or on behalf of any other Guarantor in respect of the obligations of such other Guarantor under this Article 8, result in the obligations of such Guarantor under its 2021
Note Guarantee not constituting a fraudulent transfer or conveyance. 
 Section 8.03. Execution and Delivery
of 2021 Note Guarantee. To evidence its 2021 Note Guarantee set forth in Section 8.01, each Guarantor hereby agrees that a notation of such 2021 Note Guarantee substantially in the form included in Exhibit B shall be endorsed by
an Officer of such Guarantor on each 2021 Note authenticated and delivered by the Trustee and that this Supplemental Indenture shall be executed on behalf of such Guarantor by its President or one of its Vice Presidents. 

Each Guarantor hereby agrees that its 2021 Note Guarantee as set forth in Section 8.01 shall remain in full force and effect
notwithstanding any failure to endorse on each 2021 Note a notation of such 2021 Note Guarantee. 
 If an Officer whose
signature is on this Supplemental Indenture or on the 2021 Note Guarantee no longer holds that office at the time the Trustee authenticates the 2021 Note on which a 2021 Note Guarantee is endorsed, the 2021 Note Guarantee shall be valid
nevertheless. 
 The delivery of any 2021 Note by the Trustee, after the authentication thereof hereunder, shall constitute due
delivery of the 2021 Note Guarantee set forth in this Supplemental Indenture on behalf of the Guarantors. 
 In the event that
the Company creates or acquires any new Subsidiaries subsequent to the date of this Supplemental Indenture, the Company shall cause such Subsidiaries to execute a joinder to this Supplemental Indenture in substantially the form of Exhibit C hereto
and 2021 Note Guarantees in accordance with this Article 8, to the extent applicable. 
 Section 8.04.
Guarantors May Consolidate, etc., on Certain Terms. Except as otherwise provided in Section 8.05, no Guarantor may sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into
(whether or not such Guarantor is the surviving Person) another Person whether or not affiliated with such Guarantor unless: 

(a) subject to Section 8.05 hereof, the Person acquiring the property in any such sale or disposition or the Person formed by or
surviving any such consolidation or merger (if other than a Guarantor or the Company) unconditionally assumes all the obligations of such Guarantor, pursuant to a supplemental indenture in form and substance reasonably satisfactory to the

  
 -35-

 
Trustee or by operation of law, under the 2021 Notes, this Supplemental Indenture and the 2021 Note Guarantee on the terms set forth herein or therein; and 

(b) immediately after giving effect to such transaction, no Default or Event of Default exists. 

In case of any such consolidation, merger, sale or conveyance and upon the assumption by the successor Person, by operation of law or by
supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the 2021 Note Guarantee endorsed upon the 2021 Notes and the due and punctual performance of all of the covenants and conditions of this
Supplemental Indenture to be performed by the Guarantor, such successor Person shall succeed to and be substituted for the Guarantor with the same effect as if it had been named herein as a Guarantor. Such successor Person thereupon may cause to be
signed any or all of the 2021 Note Guarantees to be endorsed upon all of the 2021 Notes issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee. All the 2021 Note Guarantees so issued shall in all
respects have the same legal rank and benefit under this Supplemental Indenture as the 2021 Note Guarantees theretofore and thereafter issued in accordance with the terms of this Supplemental Indenture as though all of such 2021 Note Guarantees had
been issued at the date of the execution hereof. 
 Except as set forth in Articles 8 and 10 of the Base Indenture and Articles
5 and 6 hereof, and notwithstanding clauses (a) and (b) above, nothing contained in this Supplemental Indenture or in any of the 2021 Notes shall prevent any consolidation or merger of a Guarantor with or into the Company or another
Guarantor, or shall prevent any sale or conveyance of the property of a Guarantor as an entirety or substantially as an entirety to the Company or another Guarantor. 
 Section 8.05. Releases.  
 A Guarantor will be released
and relieved of its obligations under the 2021 Note Guarantee upon the occurrence of any of the events set forth in this Section 8.05. 
 (a) In the event of a sale or other disposition of all of the assets of such Guarantor, by way of merger, consolidation or otherwise, or a sale or other disposition of all of the Capital Stock of such
Guarantor, in each case to a Person that is not (either before or after giving effect to such transactions) a Subsidiary of the Company if, after giving effect to such transaction, neither the Person acquiring such Capital Stock nor such Guarantor
has outstanding or guarantees any Specified Indebtedness, then such Guarantor (in the event of a sale or other disposition, by way of merger, consolidation or otherwise, of all of the Capital Stock of such Guarantor) or the corporation acquiring the
property (in the event of a sale or other disposition of all or substantially all of the assets of such Guarantor) will be released and relieved of its obligations under its 2021 Note Guarantee. 

(b) In the event the Company designates such Guarantor to be an Unrestricted Subsidiary in accordance with this Supplemental Indenture,
such Guarantor shall be released and relieved of its obligations under its 2021 Note Guarantee. 

  
 -36-

 (c) In the event such Guarantor shall cease (or simultaneously with the release of its
Guarantee hereunder shall cease) to have outstanding or guarantee any Specified Indebtedness, such Guarantor shall be released and relieved of its obligations under its 2021 Note Guarantee. 

Upon delivery by the Company to the Trustee of an Officers’ Certificate and an Opinion of Counsel to the effect that such sale or
other disposition was made by the Company in accordance with the provisions of this Supplemental Indenture, or upon delivery by the Company to the Trustee of an Officers’ Certificate to the effect that the applicable Guarantor has ceased (or
simultaneously with the release of its 2021 Note Guarantee hereunder shall cease) to have outstanding or guarantee any Specified Indebtedness or that the applicable Guarantor has been designated as an Unrestricted Subsidiary in accordance with the
provisions of this Supplemental Indenture, the Trustee shall execute any documents reasonably required in order to evidence the release of any Guarantor from its obligations under its 2021 Note Guarantee. 

Any Guarantor not released from its obligations under its 2021 Note Guarantee shall remain liable for the full amount of principal of and
interest on the 2021 Notes and for the other obligations of any Guarantor under this Supplemental Indenture as provided in this Article. 
 [Signature Pages Follow] 

  
 -37-

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed, and their respective corporate seals to be hereunto affixed and attested; all as of the day and year first written above. 
  

			
	COMPANY:
	
	AMERISOURCEBERGEN CORPORATION
		
	By:	 	 /s/ J. F. Quinn

	Name:	 	J. F. Quinn
	Title:	 	Vice President and Corporate Treasurer

 Attest: 
  

					
	By:	 	 /s/ John G. Chou

		 	Name:	 	John G. Chou
		 	Title:	 	Executive Vice President, General Counsel and Secretary

  
 Signature
Page to Supplemental Indenture 

			
	GUARANTORS:
	
	 AMBULATORY PHARMACEUTICAL SERVICES, INC.
 AMERISOURCE HEALTH SERVICES CORPORATION
 AMERISOURCEBERGEN CONSULTING SERVICES, INC.

AMERISOURCEBERGEN DRUG CORPORATION

AMERISOURCEBERGEN HOLDING CORPORATION

AMERISOURCEBERGEN SERVICES CORPORATION

AMERISOURCEBERGEN SPECIALTY GROUP, INC.
 ANDERSON
PACKAGING, INC.
 APS ENTERPRISES HOLDING COMPANY, INC.
 ASD SPECIALTY HEALTHCARE, INC.
 AUTOMED TECHNOLOGIES, INC.

BELLCO DRUG CORP.
 CLINICAL OUTCOMES RESOURCE
APPLICATION CORPORATION
 DIALYSIS PURCHASING ALLIANCE, INC.
 HEALTH SERVICES CAPITAL CORPORATION
 I.G.G. OF AMERICA, INC.

IHS ACQUISITION XXX, INC.
 IMEDEX, LLC

INTEGRATED COMMERCIALIZATION SOLUTIONS, INC.

INTERNATIONAL ONCOLOGY NETWORK SOLUTIONS, INC.

INTRINSIQ, LLC
 INTRINSIQ HOLDINGS,
INC.
 LIBERTY ACQUISITION CORP.

MEDICAL INITIATIVES, INC.
 PHARM PLUS
ACQUISITION, INC.
 PREMIER SOURCE, LLC

PREMIER SOURCE DIAGNOSTICS INC.
 SOLANA BEACH,
INC.
 SPECIALTY PHARMACY, INC.

SPECIALTY PHARMACY OF CALIFORNIA, INC.

TELEPHARMACY SOLUTIONS, INC.
 THE LASH GROUP,
INC.
 US BIOSERVICES CORPORATION
 VALUE
APOTHECARIES, INC.
 XCENDA, L.L.C.

		
	By:	 	 /s/ J. F. Quinn

	Name:	 	J. F. Quinn
	Title:	 	Vice President and Corporate Treasurer

 Attest: 
  

					
	By:	 	 /s/ John G. Chou

		 	Name:	 	John G. Chou
		 	Title:	 	Senior Vice President, General Counsel and Secretary

  
 Signature
Page to Supplemental Indenture 

			
	AMERISOURCE HERITAGE CORPORATION
		
	By:	 	 /s/ Daniel T. Hirst

	Name:	 	Daniel T. Hirst
	Title:	 	Vice President and Treasurer

 Attest: 
  

					
	By:	 	 /s/ Diana Dunphy

		 	Name:	 	Diana P. Dunphy
		 	Title:	 	Secretary

  

			
	INTERNATIONAL PHYSICIAN NETWORKS, L.L.C.
		
	By:	 	 /s/ John G. Chou

	Name:	 	John G. Chou
	Title:	 	Senior Vice President, General Counsel and Secretary

 Attest: 
  

					
	By:	 	 /s/ Diana Dunphy

		 	Name:	 	Diana P. Dunphy
		 	Title:	 	Assistant Secretary

  

					
	PHARMACY HEALTHCARE SOLUTIONS, LTD.
		
	BY:	 	 VALUE APOTHECARIES, INC.,
 AS GENERAL PARTNER

			
		 	By:	 	 /s/ J. F. Quinn

		 	 Name: J. F. Quinn

Title: Vice President and Corporate Treasurer

 Attest: 
  

					
	By:	 	 /s/ John G. Chou

		 	Name:	 	John G. Chou
		 	Title:	 	Senior Vice President, General Counsel and Secretary

  
 Signature
Page to Supplemental Indenture 

			
	TRUSTEE:
	
	U.S. BANK NATIONAL ASSOCIATION
		
	By:	 	 /s/ George J. Rayzis

	Name:	 	George J. Rayzis
	Title:	 	Vice President

 Attest: 
  

			
	By:	 	 /s/ Stephen J. Kaba

		 	Name: Stephen J. Kaba
		 	Title: Vice President

  
 Signature
Page to Supplemental Indenture 

			
	Commonwealth of Pennsylvania	  	
	ss.:	  	
	County of Chester	  	

 On the 14th day of November before me personally came J. F. Quinn, to me known, who, being by me duly
sworn, did depose and say that he resides at 21 Sloan Road, West Chester, PA 19382; that he is the Vice President and Corporate Treasurer of AmerisourceBergen Corporation, one of the parties described in and which executed the above instrument, and
of certain of the Guarantors, which are described in and which executed the above instrument; that he knows the corporate seals of said entities, as applicable; that the seals affixed to that instrument are such corporate seals; that each seal was
affixed by authority of the board of directors or committee serving a similar function of said entities; and that he signed his name thereto by like authority. 

 

	
	Vicki L. Earlen
	
	 /s/ Vicki L. Earlen

	Notary Public, Commonwealth of Pennsylvania
	Qualified in Chester County
	My Commission Expires: May 19, 2013

 Notarial Seal 

  
 Notary Page
to Supplemental Indenture 

			
	Commonwealth of Pennsylvania	  	
	ss.:	  	
	County of Chester	  	

 On the 14th day of November before me personally came Daniel T. Hirst, to me known, who, being by me duly
sworn, did depose and say that he resides at 914 Surrey Road, Wallingford, PA 19086; that he is the Vice President and Treasurer of AmeriSource Heritage Corporation, one of the parties described in and which executed the above instrument; that he
knows the corporate seal of said corporation; that the seal affixed to that instrument is such corporate seal; that it was affixed by authority of the board of directors of said corporation; and that he signed his name thereto by like authority.

  

	
	Vicki L. Earlen
	
	 /s/ Vicki L. Earlen

	Notary Public, Commonwealth of Pennsylvania
	Qualified in Chester County
	My Commission Expires: May 19, 2013

 Notarial Seal 

  
 Notary Page
to Supplemental Indenture 

			
	Commonwealth of Pennsylvania	  	
	ss.:	  	
	County of Chester	  	

 On the 14th day of November before me personally came John G. Chou, to me known, who, being by me duly
sworn, did depose and say that he resides at 508 Cynwyd Circle, Bala Cynwyd, PA 19004; that he is the Senior Vice President, General Counsel and Secretary of International Physician Networks, L.L.C., one of the parties described in and which
executed the above instrument; that he knows the corporate seal of said corporation; that the seal affixed to that instrument is such corporate seal; that it was affixed by authority of the board of directors of said corporation; and that he signed
his name thereto by like authority. 
  

	
	Vicki L. Earlen
	
	 /s/ Vicki L. Earlen

	Notary Public, Commonwealth of Pennsylvania
	Qualified in Chester County
	My Commission Expires: May 19, 2013

 Notarial Seal 

  
 Notary Page
to Supplemental Indenture 

			
	Commonwealth of Pennsylvania	  	
	ss.:	  	
	County of Philadelphia	  	

 On the 14th day of November before me personally came George J. Rayzis, to me known, who, being by me
duly sworn, did depose and say that he resides at 10 Turtle Creek Drive, Mullica Hill, NJ 08062 ; that he is the Vice President of U.S. Bank National Association, one of the parties described in and which executed the above instrument; that he knows
the corporate seal of said corporation; that the seal affixed to that instrument is such corporate seal; that it was affixed by authority of the board of directors of said corporation; and that he signed his name thereto by like authority.

  

	
	Name
	
	 /s/ Eileen Cassidy

	Notary Public, State of PA
	No.                             
   
	Qualified in Philadelphia County
	Commission Expires 8/19/15

 Notarial Seal 

  
 Notary Page
to Supplemental Indenture 

 EXHIBIT A 
 FORM OF 2021 NOTE 
 (Face of 2021 Note) 

THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE INDENTURE, TOGETHER WITH ALL SUPPLEMENTAL INDENTURES THERETO, GOVERNING THIS GLOBAL
NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO SECTION
3.05 OF THE INDENTURE, (II) THIS GLOBAL NOTE MAY BE EXCHANGED IN WHOLE BUT NOT IN PART PURSUANT TO SECTION 3.05 OF THE INDENTURE, (III) THIS GLOBAL NOTE MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO SECTION 3.09 OF THE INDENTURE AND
(IV) THIS GLOBAL NOTE MAY BE TRANSFERRED TO A SUCCESSOR DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY. 
 UNLESS AND UNTIL IT
IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM, THIS GLOBAL NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW
YORK, NEW YORK) (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS MAY BE REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH OTHER ENTITY AS MAY BE REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 Registered 

CUSIP No.
                         
 ISIN No.                              

No.             
$                                 

AMERISOURCEBERGEN CORPORATION 
 promises to pay to CEDE & CO., or registered assigns, 
 the principal sum of
                                         
                    on November 15, 2021 

Interest Payment Dates: May 15 and November 15 
 Record Dates: May 1 and November 1 
 Dated: 

 

			
	AMERISOURCEBERGEN CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 A-1

 Date of Authentication: 
 This is one of the Global 2021 Notes 
 referred to in the within-mentioned 

Supplemental Indenture: 
 Dated: 

 

			
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

  
 A-2

 (Back of 2021 Note) 
 3.500% Senior Notes due 2021 
 Capitalized terms used herein have the meanings assigned to them in
the Supplemental Indenture referred to below unless otherwise indicated. 
 1.
INTEREST. AmerisourceBergen Corporation, a Delaware corporation (the “Company”), promises to pay interest on the principal amount of this 2021 Note at 3.500% per
annum from the date hereof until maturity. The Company will pay interest semi-annually on May 15 and November 15 of each year, or if any such day is not a Business Day, on the next succeeding Business Day (each an “Interest Payment
Date”). Interest on the 2021 Notes will accrue from the most recent date to which interest has been paid or, if no interest has been paid, from the date of issuance; provided that if there is no existing Default in the payment of
interest, and if this 2021 Note is authenticated between a record date referred to on the face hereof and the next succeeding Interest Payment Date, interest will accrue from such next succeeding Interest Payment Date; provided,
further, that the first Interest Payment Date will be May 15, 2012. The Company will pay interest (including post-petition interest in any proceeding under any Bankruptcy Law) on overdue principal at the rate equal to the then applicable
interest rate on the 2021 Notes to the extent lawful; it will pay interest (including post-petition interest in any proceeding under any Bankruptcy Law) on overdue installments of interest at the same rate to the extent lawful. Interest will be
computed on the basis of a 360-day year of twelve 30-day months. 
 2. METHOD OF
PAYMENT. The Company will pay interest on the 2021 Notes (except defaulted interest) to the Persons who are registered Holders of 2021 Notes at the close of business on the
May 1 or November 1 next preceding the Interest Payment Date, even if such 2021 Notes are canceled after such record date and on or before such Interest Payment Date, except as provided in Section 3.07 of the Base Indenture with
respect to defaulted interest. Principal, premium, if any, and interest on the 2021 Notes will be payable at the office or agency of the Paying Agent and Registrar within the City of Philadelphia in the Commonwealth of Pennsylvania or, at the option
of the Company, payment of interest may be made by check mailed to the Holders of the 2021 Notes at their respective addresses set forth in the register of Holders of 2021 Notes; provided that all payments of principal, premium and interest
with respect to 2021 Notes, the Holders of which have given wire transfer instructions to the Trustee, will be required to be made by wire transfer of immediately available funds to the accounts specified by the Holders thereof. Such payment will be
in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. 
 3. PAYING AGENT AND REGISTRAR. Initially, U.S. Bank National Association, the
Trustee under the Indenture (as defined below), will act as Paying Agent and Registrar. The Company may change any Paying Agent or Registrar without notice to any Holder. The Company or any of its Subsidiaries may act in any such capacity.

 4. INDENTURE. This 2021 Note is one of a duly
authenticated series of securities of the Company issued and to be issued in one or more series under an indenture (the “Base  

  
 A-3

 
Indenture”), dated as of November 19, 2009, between the Company and the Trustee, as supplemented and amended by the Second Supplemental Indenture (the “Supplemental
Indenture” and, together with the Base Indenture, the “Indenture”), dated as of November 14, 2011, among the Company, the Guarantors and the Trustee. The terms of the 2021 Notes include those stated in the Indenture
and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended (15 U.S. Code Sections 77aaa-77bbbb). The 2021 Notes are subject to all such terms, and Holders are referred to the Indenture and such Act for a
statement of such terms. To the extent any provision of this 2021 Note conflicts with the express provisions of the Indenture, the provisions of this 2021 Note will govern and be controlling. The Company will be entitled to issue Additional 2021
Notes pursuant to Section 2.08 of the Supplemental Indenture. 
 5. OPTIONAL
REDEMPTION. (a) Except as set forth in Paragraph 5(b) hereof, the Company shall have the option to redeem the 2021 Notes, in whole or in part at any time and from time to time prior to
August 15, 2021, at a Redemption Price (expressed as percentage of principal amount) equal to the greater of: 
 (i) 100%
of the principal amount thereof; or 
 (ii) as determined by an Independent Investment Banker, the sum of the present values of
the Remaining Scheduled Payments discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Adjusted Treasury Rate; 
 in each case plus accrued and unpaid interest thereon, if any, to the applicable Redemption Date. 
 (b) On and after August 15, 2021, the Company shall have the option to redeem the 2021 Notes, in whole or in part at any time and from time to time, at a Redemption Price (expressed as percentage of
principal amount) equal to 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest thereon, if any, to the applicable Redemption Date. 
 (c) Unless the Company defaults in payment of the Redemption Price, on and after the Redemption Date, interest will cease to accrue on the 2021 Notes or portion thereof called for redemption. 

(d) Any redemption pursuant to this paragraph shall be made pursuant to the provisions of Section 11.01 through Section 11.07
of the Base Indenture. 
 6. MANDATORY
REDEMPTION. Except as set forth in Paragraph 7 below, the Company shall not be required to make mandatory redemption or sinking fund payments with respect to the 2021 Notes.

 7. REPURCHASE AT OPTION OF
HOLDER. Upon the occurrence of a Change of Control Triggering Event, unless the Company has exercised its right to redeem the 2021 Notes as described in Paragraph 5 hereof
within 60 days after the Change of Control Triggering Event, each Holder shall have the right to require the Company to purchase all or a portion (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of such Holder’s 2021 Notes
(the 

  
 A-4

 
“Change of Control Offer”) at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase (the
“Change of Control Payment”), subject to the rights of the Holders of the 2021 Notes on the relevant Record Date to receive interest due on the relevant Interest Payment Date. Within 30 days following the date upon which the Change
of Control Triggering Event occurred, or at the Company’s option, prior to any Change of Control but after public announcement of the pending Change of Control, the Company shall send, by first class mail, a notice to each Holder of the 2021
Notes, with a copy to the Trustee, which notice shall govern the terms of the Change of Control Offer, describing the transaction or transactions that constitute the Change of Control Triggering Event and setting forth the procedures governing the
Change of Control Offer as required by Section 5.04 of the Supplemental Indenture. 
 8. NOTICE
OF REDEMPTION. Notice of redemption will be mailed at least 30 days but not more than 60 days before the Redemption Date to each Holder whose 2021 Notes are to
be redeemed at its registered address. 2021 Notes in denominations larger than $2,000 may be redeemed in part but only in whole multiples of $1,000, unless all of the 2021 Notes held by a Holder are to be redeemed. Subject to any conditions
precedent that may be applicable, on and after the Redemption Date interest ceases to accrue on 2021 Notes or portions thereof called for redemption. 
 9. DENOMINATIONS, TRANSFER, EXCHANGE. The 2021 Notes are in registered form without coupons in
denominations of $2,000 and integral multiples of $1,000 in excess thereof. 2021 Notes may be transferred or exchanged as provided in the Indenture. The Registrar and the Trustee may require a Holder, among other things, to furnish appropriate
endorsements and transfer documents and the Company may require a Holder to pay any taxes and fees required by law or permitted by the Indenture. The Company need not exchange or transfer any 2021 Note or portion of a 2021 Note selected for
redemption, except for the unredeemed portion of any 2021 Note being redeemed in part. Also, the Company need not exchange or register the transfer of any 2021 Notes for a period of 15 days before a selection of 2021 Notes to be redeemed or during
the period between a record date and the corresponding Interest Payment Date. 
 10. PERSONS
DEEMED OWNERS. The registered Holder of a 2021 Note may be treated as its owner for all purposes. 

11. AMENDMENT, SUPPLEMENT AND
WAIVER.  
 (a) The Base Indenture may be amended as
provided therein. Subject to certain exceptions, the Supplemental Indenture, the 2021 Note Guarantees or the 2021 Notes may be amended or supplemented with the consent of the Holders of not less than a majority in principal amount of the 2021 Notes
(including Additional 2021 Notes under the Supplemental Indenture, if any). The Holders of not less than a majority in principal amount of the 2021 Notes (including Additional 2021 Notes, if any) may waive any past default with respect to the 2021
Notes and its consequences, except a default not theretofore cured in the payment of principal, premium, if any, or interest, if any, on the 2021 Notes (except a payment default resulting from an acceleration that has been rescinded), or in respect
of a covenant or provision in Article 4 of the Supplemental Indenture that cannot be modified or amended without the consent of the Holder of each 2021 Note. 

  
 A-5

 (b) Without the consent of any Holder of a 2021 Note, the Supplemental Indenture, the 2021
Note Guarantees or the 2021 Notes may be amended or supplemented: 
 (i) to evidence the succession of another corporation to
the Company or any Guarantor, or successive successions, and the assumption by any such successor of the covenants, agreements and obligations of the Company and such Guarantor pursuant to Article 6 and Section 8.04 of the Supplemental
Indenture; or 
 (ii) to add to the covenants of the Company such further covenants, restrictions or conditions for the
protection of the Holders of the 2021 Notes as the Company and the Trustee shall consider to be for the protection of the Holders of the 2021 Notes or to surrender any right or power therein conferred upon the Company; or 

(iii) to cure any ambiguity, to correct or supplement any provision therein which may be inconsistent with any other provision therein or
in any supplemental indenture thereto, or to make any other provisions with respect to matters or questions arising under the Supplemental Indenture that do not adversely affect the interests of the Holders of the 2021 Notes in any material respect;
or 
 (iv) to add to the Supplemental Indenture such provisions as may be expressly permitted by the TIA, excluding, however,
the provisions referred to in Section 316(a)(2) of the TIA as in effect at the date as of which this instrument is executed or any corresponding provision in any similar federal statute hereafter enacted; or 

(v) to add guarantors or co-obligors with respect to the 2021 Notes; or 

(vi) to secure the 2021 Notes; or 
 (vii) to add to the rights of the Holders of the 2021 Notes; or 
 (viii) to
evidence and provide for the acceptance of appointment by another corporation as a successor Trustee hereunder with respect to the 2021 Notes and to add to or change any of the provisions of the Supplemental Indenture as shall be necessary to
provide for or facilitate the administration of the trusts hereunder by more than one Trustee, pursuant to Section 6.11 of the Base Indenture; or 
 (ix) to add any additional Events of Default in respect of the 2021 Notes; or 

(x) to comply with the requirements of the Commission in connection with the qualification of the Supplemental Indenture under the TIA;
or 
 (xi) to conform the text of the Supplemental Indenture, the 2021 Notes or the 2021 Note Guarantees to any provision of the
“Description of Notes” section of the Company’s Prospectus Supplement dated November 8, 2011, relating to the initial offering of the 2021 Notes, to the extent that such provision in the “Description of Notes” was
intended to be a verbatim recitation of a provision of the Supplemental Indenture, the 2021 Notes or the Guarantees; or 

  
 A-6

 (xii) to allow any Guarantor to execute a joinder to the Supplemental Indenture and/or a
2021 Note Guarantee with respect to the 2021 Notes. 
 12. DEFAULTS AND
REMEDIES. Events of Default include: 
 (i) default in
the payment of any interest on the 2021 Notes when it becomes due and payable, and continuance of such default for a period of 30 days; or 
 (ii) default in the payment of the principal amount of (or premium, if any, on) the 2021 Notes as and when the same shall become due, either at Stated Maturity, upon redemption, by declaration, or
otherwise; or 
 (iii) default, subject to the provisions of Section 10.06 of the Base Indenture, in the performance or
breach of any covenant or warranty of the Company in the Base Indenture or the Supplemental Indenture (other than a covenant or warranty a default in the performance of which or the breach of which is elsewhere in this Section specifically dealt
with), and continuance of such default or breach for a period of 90 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount
of the 2021 Notes, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or 

(iv) the entry of an order for relief against the Company or any of its Significant Subsidiaries or any group of its Restricted
Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, under Bankruptcy Law by a court having jurisdiction in the premises or a decree or order by a court having jurisdiction in the premises adjudging the Company, the
Significant Subsidiary or such group of Restricted Subsidiaries a bankrupt or insolvent under any other applicable Federal or State law, or the entry of a decree or order approving as properly filed a petition seeking reorganization, arrangement,
adjustment or composition of or in respect of the Company, or any of its Significant Subsidiaries or any group of its Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, under Bankruptcy Law or any other
applicable Federal or State law, or appointing a receiver, liquidator, assignee, trustee, sequestrator (or other similar official) of the Company, or any of its Significant Subsidiaries or any group of its Restricted Subsidiaries that, taken as a
whole, would constitute a Significant Subsidiary, or of any substantial part of their respective property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period
of 90 consecutive days; or 
 (v) the consent by the Company, or any of its Significant Subsidiaries or any group of its
Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary, to the institution of bankruptcy or insolvency proceedings against it, or the filing by them of a petition or answer or consent seeking reorganization or
relief under Bankruptcy Law or any other applicable Federal or State law, or the consent by them to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee, sequestrator (or other similar official) of the
Company, the Significant Subsidiary or such group of Restricted Subsidiaries or of any substantial part of their respective property, or the making by it of an assignment for the benefit of creditors, or the admission by them in writing of their
inability to 

  
 A-7

 
pay their debts generally as they become due, or the taking of corporate action by the Company, the Significant Subsidiary or such group of Restricted Subsidiaries in furtherance of any such
action; 
 (vi) failure by the Company or any of its Restricted Subsidiaries to comply with Section 5.04 of the
Supplemental Indenture, and continuance of such default for a period of 30 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal
amount of the 2021 Notes of a Notice of Default; 
 (vii) default under any mortgage, indenture or instrument under which there
may be issued or by which there may be secured or evidenced any Indebtedness for money borrowed by the Company or any of its Restricted Subsidiaries (or the payment of which is guaranteed by the Company or any of its Subsidiaries), whether such
Indebtedness or Guarantee now exists, or is created after the date of the Supplemental Indenture, which (i) is caused by the failure to pay principal of, or interest or premium, if any, on such Indebtedness prior to the expiration of the grace
period provided in such Indebtedness on the date of such default (a “Payment Default”), and (ii) results in the actual acceleration of such Indebtedness prior to its express maturity, and, in each case, the principal amount of
such Indebtedness, together with the principal amount of any other such Indebtedness under which there has been a Payment Default or the maturity of which has been so accelerated, aggregates $50.0 million or more; 

(viii) a final judgment or final judgments for the payment of money are entered by a court or courts of competent jurisdiction against
the Company or any of its Significant Subsidiaries or any group of Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary and such judgment or judgments remain undischarged for a period (during which execution shall not be
effectively stayed pending appeal (or otherwise stayed)) of 60 days, provided that the aggregate of all such undischarged judgments exceeds $50.0 million (net of any amount covered by insurance); 

(ix) except as permitted by the Supplemental Indenture, any 2021 Note Guarantee is held in any judicial proceeding to be unenforceable or
invalid or shall cease for any reason to be in full force and effect or any Guarantor, or any Person acting on behalf of any Guarantor, shall deny or disaffirm its obligations under such Guarantor’s 2021 Note Guarantee. 

If any Event of Default occurs and is continuing, the Trustee may declare all the 2021 Notes to be due and payable immediately, and upon
receipt of written instructions from the Holders of at least 25% in principal amount of the then outstanding 2021 Notes, the Trustee will declare all the 2021 Notes to be due and payable. Notwithstanding the foregoing, in the case of an Event of
Default arising from certain events of bankruptcy or insolvency, with respect to the Company or any Significant Subsidiary or any group of Restricted Subsidiaries that, taken as a whole, would constitute a Significant Subsidiary pursuant to or
within the meaning of Bankruptcy Law, all outstanding 2021 Notes will become due and payable without further action or notice. Holders may not enforce the Supplemental Indenture or the 2021 Notes except as provided in the Indenture. Subject to
certain limitations, Holders of a majority in aggregate principal amount of the 2021 Notes may direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders of the 2021 Notes notice of any continuing Default or

  
 A-8

 
Event of Default if it determines that withholding notice is in their interest, except a Default or Event of Default relating to the payment of principal or interest. The Holders of a majority in
aggregate principal amount of the 2021 Notes then outstanding by notice to the Trustee may on behalf of the Holders of all of the 2021 Notes waive any existing Default or Event of Default and its consequences under the Supplemental Indenture except
a continuing Default or Event of Default in the payment of interest on, or the principal of, the 2021 Notes or as otherwise provided under Section 11. The Company is required to deliver to the Trustee annually a statement regarding compliance
with the Indenture, and the Company is required upon becoming aware of any Default or Event of Default, to deliver to the Trustee a statement specifying such Default or Event of Default. 

13. TRUSTEES DEALINGS WITH
COMPANY. The Trustee, in its individual or any other capacity, may make loans to, accept deposits from, and perform services for the Company or its Affiliates, and may
otherwise deal with the Company or its Affiliates, as if it were not the Trustee. 
 14. NO
RECOURSE AGAINST OTHERS. A director, officer, employee, incorporator or stockholder, of the Company or any Guarantor, as such, shall not have any
liability for any obligations of the Company or the Guarantors under the 2021 Notes, the 2021 Note Guarantees or the Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of
2021 Notes by accepting a 2021 Note waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2021 Notes. 
 15. AUTHENTICATION. This 2021 Note shall not be valid until authenticated by the manual signature of the Trustee or an
authenticating agent. 
 16. ABBREVIATIONS.
Customary abbreviations may be used in the name of a Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (=
Custodian), and U/G/M/A (= Uniform Gifts to Minors Act). 
 17. CUSIP
NUMBERS. Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused CUSIP numbers to be printed on the
2021 Notes and the Trustee may use CUSIP numbers in notices of redemption as a convenience to Holders. No representation is made as to the accuracy of such numbers either as printed on the 2021 Notes or as contained in any notice of redemption and
reliance may be placed only on the other identification numbers placed thereon. The Company will furnish to any Holder upon written request and without charge a copy of the Base Indenture, the Supplemental Indenture and the Guarantees. Requests may
be made to: 
 AmerisourceBergen Corporation 
 1300 Morris Drive 
 Chesterbrook, Pennsylvania 19087-5594 

Attention: Vice President and Treasurer 

  
 A-9

 ASSIGNMENT FORM 

To assign this 2021 Note, fill in the form below: 
 (I) or (we) assign and transfer this 2021 Note 
  

					
	to:	 	  
	  	
		 		  	(Insert assignee’s legal name)

  

	
	  

	(Insert assignee’s social security or tax identification number)

  

	
	  

	  

	  

	  

	(Print or type assignee’s name, address and zip code)

  

			
	and irrevocably appoint	 	  

 to transfer this 2021 Note on the books of the Company. The agent may substitute another to act for him. 

Date:                        
             
  

													
		 	Your Signature:	 	  

		 	
(Sign exactly as your name appears on the face of this 2021 Note)

			
		 	Tax Identification Number:	 	  

			
		 	Signature Guarantee:	 	  

 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar,
which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in
substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended. 

  
 A-10

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this 2021 Note purchased by the Company pursuant to Section 5.04 of the Supplemental Indenture, check
the box below: 
  ̈ Section 5.04 

If you want to elect to have only part of the 2021 Note purchased by the Company pursuant to Section 5.04 of the Supplemental
Indenture, state the amount you elect to have purchased: 

$                     

Date:                      

 

													
		 	Your Signature:	 	  

		 	
(Sign exactly as your name appears on the face of this 2021 Note)

			
		 	Tax Identification Number:	 	  

			
		 	Signature Guarantee:	 	  

 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar,
which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in
substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended. 

  
 A-11

 SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL NOTE * 

The following exchanges of a part of this Global 2021 Note for an interest in another Global 2021 Note or for note in definitive form, or
exchanges of a part of another Global 2021 Note or note in definitive form for an interest in this Global 2021 Note, have been made: 
  

									
	 Date of Exchange
	  	Amount of
decrease in
Principal Amount
of this Global 
2021
Note	  	Amount of Increase
in Principal
Amount of this
Global 2021 
Note	  	Principal Amount
of this Global 2021
Note following such
decrease 
(or
increase)	  	Signature of
authorized officer
of Trustee or 2021
Note Custodian
		  		  		  		  	

  

	*	This schedule should be included only if the 2021 Note is issued in global form. 

  
 A-12

 EXHIBIT B 
 FORM OF NOTATION OF GUARANTEE 
 For value received, each of the Guarantors
(which term includes any successor Person under the Supplemental Indenture (as hereinafter defined)) has, jointly and severally, unconditionally guaranteed, to the extent set forth and subject to the provisions in the Indenture, dated as of
November 19, 2009 (the “Base Indenture”), by and among AmerisourceBergen Corporation (the “Company”) and U.S. Bank National Association, as trustee (the “Trustee”), as amended and supplemented
by the Second Supplemental Indenture (the “Supplemental Indenture”), dated as of November 14, 2011, by and among the Company, the Guarantors named on the signature pages thereto and the Trustee (the Base Indenture as amended
and supplemented by the Supplemental Indenture is hereinafter referred to as the “Indenture”), (a) the due and punctual payment of the principal of, premium, if any, and interest on the 2021 Notes (as defined in the
Supplemental Indenture), whether at maturity, by acceleration, redemption or otherwise, the due and punctual payment of interest on overdue principal and premium, and, to the extent permitted by law, interest, and the due and punctual performance of
all other obligations of the Company to the Holders or the Trustee all in accordance with the terms of the Indenture and (b) in case of any extension of time of payment or renewal of any 2021 Notes or any of such other obligations, that the
same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise. The obligations of the Guarantors to the Holders of 2021 Notes and to the
Trustee pursuant to the 2021 Note Guarantee are expressly set forth in Article 8 of the Supplemental Indenture and reference is hereby made to the Supplemental Indenture for the precise terms of the 2021 Note Guarantee. Each Holder of a 2021 Note,
by accepting the same, agrees to and will be bound by such provisions and appoints the Trustee attorney-in-fact of such Holder for such purpose. 
  

			
	[Name of Guarantor(s)]
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 B-1

 EXHIBIT C 
 FORM OF JOINDER TO SECOND SUPPLEMENTAL INDENTURE 
 TO BE DELIVERED BY
SUBSEQUENT GUARANTORS 
 This JOINDER TO SECOND SUPPLEMENTAL INDENTURE (this “Joinder”), dated as of
            , 20    , among                      (the
“Guaranteeing Subsidiary”), a subsidiary of AmerisourceBergen Corporation (or its permitted successor), a Delaware corporation (the “Company”), the Company, the other Guarantors (as defined in the Second
Supplemental Indenture referred to herein) and U.S. Bank National Association, as trustee under the Second Supplemental Indenture referred to below (the “Trustee”). 

Recitals 

The Company has heretofore executed and delivered to the Trustee an indenture (the “Base Indenture”), dated as of
November 19, 2009, between the Company and the Trustee, as amended and supplemented by a second supplemental indenture thereto (the “Second Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), dated as of November 14, 2011, among the Company, the Guarantors named therein and the Trustee, providing for the original issuance of an aggregate principal amount of $500,000,000 million of the Company’s
3.500% Senior 2021 Notes due 2021 (the “2021 Notes”). 
 The Second Supplemental Indenture provides that under
certain circumstances the Guaranteeing Subsidiary will execute and deliver to the Trustee a joinder to Second Supplemental Indenture pursuant to which the Guaranteeing Subsidiary will unconditionally guarantee all of the Company’s Obligations
under the 2021 Notes and the Indenture on the terms and conditions set forth herein (the “2021 Note Guarantee”). 
 Pursuant to Section 4.01 of the Second Supplemental Indenture, the Trustee is authorized to execute and deliver this Joinder. 
 NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiary and the Trustee mutually covenant
and agree for the equal and ratable benefit of the Holders of the 2021 Notes as follows: 
 1. Capitalized Terms. Capitalized
terms used herein without definition will have the meanings assigned to them in the Second Supplemental Indenture. 
 2.
Guarantee. By execution hereof, the Guaranteeing Subsidiary hereby agrees as of the date hereof, to become and is made a party to the Second Supplemental Indenture and for all purposes under the Second Supplemental Indenture, the
Guaranteeing Subsidiary shall be included within the term “Guarantor” (as defined in the Second Supplemental Indenture). The undersigned hereby adopts and agrees to be bound by all of the agreements, terms, conditions and
restrictions of a “Guarantor” as such term is defined in the Second Supplemental Indenture and further authorizes the Trustee to attach this signature page to the First Supplemental 

  
 C-1

 
Indenture in order to make the Guaranteeing Subsidiary a party to the Second Supplemental Indenture. 
 3. Governing Law. THE INTERNAL LAW OF THE STATE OF NEW YORK WILL GOVERN AND BE USED TO CONSTRUE THIS JOINDER BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE
EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 
 4. Counterparts. The parties may
sign any number of copies of this Joinder. Each signed copy will be an original, but all of them together represent the same agreement. 
 5.
Effect of Headings. The Section headings herein are for convenience only and will not affect the construction hereof. 
 6.
The Trustee. The Trustee will not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Joinder or for or in respect of the recitals contained herein, all of which recitals are made solely by
the Guaranteeing Subsidiary and the Company. 
 [Signature Page Follows] 

  
 C-2

 IN WITNESS WHEREOF, the parties hereto have caused this Joinder to the Second Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

			
	[GUARANTEEING SUBSIDIARY]
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[COMPANY]
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[EXISTING GUARANTORS]
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[TRUSTEE], as Trustee
		
	By:	 	  

	Name:	 	Authorized Signatory
	Title:	 	

  
 C-3Joint Development Agreement

 Exhibit 10.11 

 
 JOINT DEVELOPMENT AGREEMENT 

 
 This Joint Development Agreement (this
“Agreement”) is made as of August 5, 2010 (the “Effective Date”) by and between Elevance Renewable Sciences, Inc., a Delaware corporation having its principal office at 175 E. Crossroads Parkway,
Bolingbrook, Illinois 60440 (“ERS”), and Stepan Company, a Delaware corporation, with its principal offices at 22 Frontage Road, Northfield, IL 60093 (“Stepan”). 

 
 WHEREAS, Stepan is a global manufacturer of specialty
chemicals and intermediate chemicals used in consumer products and industrial applications; 
  
 WHEREAS, ERS is a leader in developing and manufacturing modified natural oil-based products that can be made in a variety of forms including oils, blends, waxes and emulsions; and 

 
 WHEREAS, ERS and Stepan desire to collaborate by combining
technologies and competencies to develop chemical derivatives of modified natural oil-based products for use in certain fields as more fully set forth herein. 
  

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, ERS and Stepan hereby agree as follows. 
  

1. Defined Terms. 
  

Terms used herein with initial capital letters shall have the respective meanings set forth below in this Section 1. The
definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The word “will”
shall be construed to have the same meaning and effect as the word “shall,” and vice versa. 
  

1.1. “Affiliate” means, with respect to a Party, any entity that Controls, is Controlled by, or is under common Control
with, such Party. 
  
 1.2. “Commercial
Milestones” means specific revenue, volume, and profitability goals with respect to sales of Products, Developed ERS Products, and Derivatives arising from a Joint Development Activity. 

 
 1.3. “Competitor” means, with respect to a
Party, an entity designated as a competitor of such Party on Exhibit D, which Exhibit D shall be agreed upon by the Parties and attached hereto through an amendment hereto within thirty (30) days of the Effective Date. 

  
 1.4. “Confidential Information”
means (a) any confidential business information (including, without limitation, confidential information related to a Party’s products, formulas, compositions, experimental work, customers, clients or suppliers) or other proprietary,
confidential or non-public information of a Party, its affiliates or its or their directors, officers, employees, or customers or third parties to whom it owes a duty of confidentiality, including any of the foregoing provided by a Party to the
other prior to the Effective Date pursuant to a prior confidentiality agreement between the Parties, and (b) the terms of this Agreement. 

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

 
 1.5. “Control” (including with correlative
meanings, the terms “Controlling,” “Controlled by” and “under common Control with”) means the possession directly or indirectly of the power to direct or cause the direction of the management and
policies of an entity, whether through the ownership of voting securities, by trust, management agreement, contract or otherwise; provided, however, that beneficial ownership of fifty percent (50%) or more of the voting stock of
an entity shall be deemed to be Control. 
  
 1.6.
“Derivative” means a composition or material derived from a Product. 
  
 1.7. “Derivatives and Applications Intellectual Property” means Developed Intellectual Property relating to (a) [***] and the processes to create, produce, manufacture, or develop
the foregoing (including composition of matter, product by process, and process Intellectual Property and any trade secrets or Confidential Information relating to [***]), and (b) product applications relating to [***]. 

 
 1.8. “Developed Intellectual Property” means
any Intellectual Property that is made, conceived, developed, or conceived and reduced to practice, by either Party solely or jointly with the other Party (regardless of relative input, contribution or involvement), under this Agreement or otherwise
resulting from activities in the Initial Screening Phase or Joint Development Activities. 
  
 1.9. “Developed ERS Product” means a new Product that is developed for or in connection with the Initial Screening Phase or a Joint Development Activity, but excluding compositions or
materials derived from existing Products. 
  
 1.10.
“Development Milestones” means specific milestones for development of Products, Developed ERS Products, and Derivatives with respect to a Joint Development Activity including timelines, resources, and/or technical accomplishments.

  
 1.11. “Development Notice” means
a written project plan for a Joint Development Activity specifying the development objectives, the expected results, and the market need. 
  

1.12. “Executive Team” means a governance group of two (2) representatives from each of ERS and Stepan, comprising
one (1) technical representative and one (1) commercial representative of each Party, that shall have responsibility for strategic decisions related to the Joint Development Activities, including modifications to the Joint Development Plan
and the setting of Milestones, and for oversight of the Technical Coordinators. 
  
 1.13. “EBIT” means earnings before interest and taxes, as calculated in accordance with generally accepted accounting principles. 
  
  1.14. “[***] Fee” means a payment to be made by Stepan to ERS [***]. Unless otherwise
specified in an applicable Joint Development Plan, [***]. 
   
 1.15. “Existing ERS Intellectual Property” means all Intellectual Property owned by, or licensed to, ERS that was or is made, conceived, developed, reduced to practice or acquired by ERS
prior to the Effective Date or independent of this Agreement or the Initial Screening Phase or the Joint Development Activities. 

  
 -2-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

1.16. “Existing Stepan Intellectual Property” means any Intellectual Property owned by, or licensed to, Stepan that was
or is made, conceived, developed, reduced to practice or acquired by Stepan prior to the Effective Date or independent of this Agreement or the Initial Screening Phase or the Joint Development Activities. 

 
 1.17. “Field” means a combination of product
and application and market fields to be evaluated by the Parties during the Initial Screening Phase that are specified in Exhibit A (and subject to the limitations set forth in such Exhibit A), as revised to reflect reduction in scope
as set forth in Section 2.4 or otherwise hereunder. 
  
 1.18. “Initial Screening Phase” means the period from the Effective Date through [***]. 
  

1.19. “Intellectual Property” means inventions, patents, patent applications, patent disclosures, innovations,
improvements, formulae, materials, compositions, original works of authorship, software, databases, developments, concepts, methods, trade secrets, designs, trademarks, trade names, analyses, drawings, reports and all similar or related information
or developments (whether or not patentable or registrable under copyright, trademark or similar laws) and all intellectual property rights and similar rights therein under any jurisdiction in the world. 

 
 1.20. “Joint Development Activity” means any
activity or undertaking to be performed by one or both of the Parties as set forth in a Joint Development Plan. 
  

1.21. “Joint Development Activity Field” shall mean that portion of the Field applicable to a Joint Development Activity,
as set forth in a Joint Development Plan, which portion of the Field shall be defined by reference to: [***]. 
  

1.22. “Joint Development Plan” means a written and signed project plan for Joint Development Activities specifying
(a) the details regarding the execution of, and objectives for, such Joint Development Activities, including the Parties’ respective roles and obligations, specific personnel of the Parties to be involved in and/or oversee such Joint
Development Activities, the applicable Joint Development Activity Field, the objective(s) of such Joint Development Activities, the Products being utilized and evaluated or tested under such Joint Development Activities, the Developed ERS Products
and Derivatives to be developed under such Joint Development Activities, the target market value for any materials developed under such Joint Development Activities, and the Parties’ expected expenses, inputs, contributions and investments with
respect to such Joint Development Activities, (b) the commercial value sharing details with respect to such Joint Development Activities, (c) the Exclusivity Fee for the Field applicable to such Joint Development Activities, (d) the
Development Milestones for such Joint Development Activities, and (e) the Commercial Milestones for such Joint Development Activities. 
  

1.23. “Milestone” means either a Commercial Milestone or a Development Milestone. 

  
 -3-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

1.24. “Natural Oils” means glyceride-based, non-petroleum-derived oils, that are produced by expression in plants or
animals, including without limitation vegetable oils, animal fats, and algal oils, and fatty acid or fatty ester derivatives from such oils. 
  

1.25. “Non-Field Applications Intellectual Property” means Developed Intellectual Property relating to product
applications outside of the Field for [***]. 
  

1.26. “Non-Metathesis Feedstock Derivate” means a composition or material derived from a Non-Metathesis Feedstock.

  
 1.27. “Non-Metathesis Feedstock”
means any feedstock not resulting from the metathesis of a Natural Oil wherein such feedstock consists essentially of: [***]. 
  

1.28. “Party” means either of ERS or Stepan. 

 
 1.29. “Product” means any feedstock
resulting from the metathesis of a Natural Oil, wherein such feedstock consists essentially of: [***]. 
  

1.30. “Product Intellectual Property” means Developed Intellectual Property relating to Products, Developed ERS Products,
or Non-Metathesis Feedstock and the processes to create, produce, manufacture, or develop the foregoing (including composition of matter, product by process, and process Intellectual Property and any trade secrets or Confidential Information
relating to Products, Developed ERS Products, or Non-Metathesis Feedstocks). 
  
 1.31. “Screening Milestone” means the Initial Screening Phase activities, expected progress, and timeline milestones for a particular Initial Screening Phase initiative, Product,
Derivative, and/or Field, as specified in Exhibit B. 
  
 1.32. “Technical Coordinator” means the representative of a Party designated to act as a liaison with his or her counterpart at the other Party for the various technical matters that may
arise during the course of the Joint Development Activities, which representative shall have an appropriate level of education, training, and experience to effectively carry out the foregoing responsibilities. 

 
 1.33. “Term” means the period from the
Effective Date through the expiration or termination of this Agreement in accordance with Article 11. 
  
 2. Initial Screening. 
  
 2.1. Initial Screening Activities. During the Initial Screening Phase, ERS and Stepan shall collaborate to evaluate and assess the development and commercialization of Products, Developed ERS
Products and Derivatives within the Fields. In connection with such collaboration, the Parties will seek to determine whether any Products, Developed ERS Products, or Derivatives are technically and commercially viable in such Fields. If Stepan
believes that additional time is necessary to conduct screening activities, Stepan may propose to ERS that the Initial Screening Phase be extended for up to an additional three (3) months, but any extension shall be subject to the express
written consent of ERS, which consent shall be granted or withheld in ERS’s sole discretion. 

  
 -4-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

2.2. Exclusivity. [***]. Nothing herein shall limit either Party from collaborating with third parties in, or supplying third
parties in connection with, markets or products other than the Fields. Notwithstanding the foregoing, ERS is expressly permitted to continue to engage in existing contractual arrangements, and to enter into new contractual arrangements, related to
research, development, testing, and analysis regarding existing and future ERS materials, technologies, and products with parties that are not commercializing such materials, technologies and products, including third party consultants,
laboratories, universities, research centers, research and development contractors, and other contractors; provided, however, that (a) ERS shall have the exclusive right under any such contractual arrangement to use and license
any Intellectual Property developed under such contractual arrangement for commercial purposes [***], and (b) ERS has the right under any such contractual arrangement to oversee or control the disclosure and commercial use of such Intellectual
Property in a manner that protects the Parties’ interests in such Intellectual Property that might have commercial applications [***]. ERS shall, during the Initial Screening Phase but subject to any confidentiality obligations ERS has to third
parties, provide Stepan a monthly update on Products, Developed ERS Products, or Derivatives arising from its own development efforts, or those efforts resulting from such contractual arrangements, that are relevant to the Fields then being
considered by Stepan in the Initial Screening Phase. 
  
 2.3. Screening Milestones. During the first thirty (30) days after the Effective Date, the Parties will mutually agree upon Screening Milestones to be in effect during the Initial Screening
Phase and shall set forth such Screening Milestones in an updated Exhibit B added through an amendment to this Agreement. During the Initial Screening Phase, Stepan shall use commercially reasonable efforts to meet the Screening Milestones
applicable to a particular Product, Developed ERS Products, and/or Derivative in a particular Field or portion of the Field. If Stepan fails to meet any such Screening Milestone, Stepan shall provide prompt notice to ERS of such failure. Such notice
shall specify the Product, Developed ERS Products and/or Derivative and the Field or portion of the Field affected by the failure to meet any such Screening Milestone. During the first thirty (30) days after the date of such notice, Stepan
shall have the right to correct such failure. If Stepan is unable to correct the failure within thirty (30) days of such notice or believes at any point prior to the end of such thirty (30) day period that it will be unable to remedy such
failure within such thirty (30) day period, Stepan may escalate the issue for discussion and escalation in accordance with the procedures set forth in Section 13.1, in which case the Parties’ escalation representatives shall
engage in good faith discussions as to whether the Screening Milestones should be modified, changed or adjusted over a period not to exceed fifteen (15) days in the aggregate. In the event Stepan is unable to correct the failure within thirty
(30) days of such notice and the Parties have not agreed to modify, change or adjust the Screening Milestones through the escalation process specified above, the exclusivity granted to Stepan pursuant to Section 2.2 only with
respect to the Product, Developed ERS Product and/or Derivative in the Field or portion of the Field to which the failure relates shall lapse, and the Parties shall be released from the restrictions and obligations with respect to such exclusivity.
The Screening Milestones shall not be modified, revised, terminated, or changed in any way except upon mutual written agreement of the Parties. Notwithstanding the foregoing, a Screening Milestone shall be equitably adjusted to the extent Stepan is
not able to meet such 

  
 -5-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
 
Screening Milestone or such Screening Milestone is not otherwise met as a result of the failure of ERS to meet any agreed-upon obligation it has in connection with the Initial Screening Phase,
with an appropriate extension to such Screening Milestone commensurate with the delay caused by such ERS failure. Stepan’s obligation to meet the Screening Milestones shall terminate upon the conclusion of the Initial Screening Phase. 

  
 2.4. Reduction in Field. During the
Initial Screening Phase, Stepan shall immediately provide notice to ERS if Stepan determines not to pursue a potential Joint Development Activity in any particular Field or portion of the Field, whether as a result of failure of technical
verification, determination that feasible or attractive commercialization opportunities do not exist, or otherwise. [***]. Upon such notice, (i) the exclusivity granted to Stepan pursuant to Section 2.2 only with respect to the
[***], and the Parties shall be released from the restrictions and obligations with respect to such exclusivity, and (ii) the Parties shall cease any and all joint development activities only with respect to the [***]. 

 
 2.5. Samples. During the Initial Screening Phase and
during the term of any Joint Development Plan, Stepan will provide to ERS reasonable quantities of sample materials of Derivatives generated during the Initial Screening Phase or under such Joint Development Plan, for ERS screening of samples of
such Derivatives for [***]. Stepan shall not provide samples of such Derivatives to third parties without first obtaining ERS’s consent, except (a) [***], and (b) provision of samples to third parties shall be bound by agreements to
Stepan that (i) require such third parties to not disclose such samples or the characteristics, properties or attributes thereof, and (ii) require such third parties to not apply for patents with respect to such Derivatives, including with
respect to the characteristics, properties, attributes or potential applications thereof. During the Initial Screening Phase and during a reasonable period of analysis under each Joint Development Plan, ERS may perform tests and analyses on such
samples provided by Stepan hereunder to assess [***]. If ERS identifies Derivatives that demonstrate [***], ERS will notify Stepan of such finding within thirty (30) business days, and the Parties will coordinate and collaborate with respect to
the development and filing of patent applications with respect thereto taking into account their respective ownership or control of Developed Intellectual Property hereunder. 

 
 3. Development Activities. 

 
 3.1. Establishment of Joint Development Activities.
During the Initial Screening Phase and for up to thirty (30) days after the conclusion of the Initial Screening Phase, if Stepan determines in good faith that a reasonable and commercially feasible opportunity exists with respect to a Product,
Developed ERS Product or Derivative in the Field, Stepan may elect to form a Joint Development Activity with respect thereto by providing to ERS a Joint Development Notice specifying the Joint Development Activities and reflecting details to
populate the categories set forth in Exhibit C for a Joint Development Plan, including proposed Milestones and other details that reflect a reasonable and good faith attempt by Stepan to ensure that the resources, efforts and scope of the
Joint Development Activity under such Joint Development Plan correspond to the size and scope of the market opportunity in connection with such Joint Development Activity and the Parties’ respective current and future resources and technical
capabilities. The Joint Development Activity Field applicable to a Joint Development 

  
 -6-

  
Activity under a Joint Development Plan shall be some portion of the Fields set forth on Exhibit A, but shall not expand or be outside of such Fields without the mutual agreement of the
Parties evidenced as an express intent to expand such Fields in the applicable Joint Development Plan. At any time thereafter the Executive team and Technical Coordinators may establish additional Joint Development Activities through the creation
and execution of additional Joint Development Plans. Upon approval of a Development Notice in writing by ERS, the activities specified therein shall constitute Joint Development Activities for purposes of this Agreement. If any portion of the Field
is not covered by a Joint Development Activity Field established within thirty (30) days of the conclusion of the Initial Screening Phase, (a) the exclusivity granted to Stepan pursuant to Section 2.2 only with respect to such
portion of the Field shall lapse, and the Parties shall be released from the restrictions and obligations only with respect to such exclusivity in such portion of the Field, and (b) the Parties shall cease any and all joint development
activities in such portion of the Field. 
  
 3.2.
Joint Development Plan. The Parties shall carry out their respective obligations with respect to the Joint Development Activities as set forth in each agreed upon Joint Development Plan, each of which shall be attached hereto as Exhibit
C and incorporated herein upon execution by the Parties. For so long as a Joint Development Plan is in place, the Parties shall work with one another to carry out their respective Joint Development Activities thereunder and seek to maximize the
value for the Parties in connection therewith, subject to the exclusivity provisions in Section 3.3. The Parties shall at all times during the Term cooperate and collaborate in good faith with respect to the Joint Development Activities
and the implementation and execution of the Joint Development Plan. In the event of any conflict or ambiguity between a term or condition of the body of this Agreement and a term or condition of the Joint Development Plan, the applicable term or
condition of the body of this Agreement shall control unless the applicable term or condition of the Joint Development Plan expressly states that it shall control over a specific term or condition of the body of this Agreement. 

 
 3.3. Development Exclusivity. For so long as a Joint
Development Plan is in place, neither Party shall, except in connection with the Joint Development Activities, undertake any activities itself, or undertake any joint development activities in collaboration with or on behalf of any third party, in
connection with the Joint Development Activity Field applicable to such Joint Development Plan. Notwithstanding the foregoing, ERS is expressly permitted to continue to engage in existing contractual arrangements, and to enter into new contractual
arrangements, related to research, development, testing, and analysis regarding existing and future ERS materials, technologies, and products with parties that are not commercializing such materials, technologies and products, including third party
consultants, laboratories, universities, research centers, research and development contractors, and other contractors; provided, however, that (a) ERS shall have the exclusive right under any such contractual arrangement to use
and license any Intellectual Property developed under such contractual arrangement for commercial purposes in the Field, and (b) ERS has the right under any such contractual arrangement to oversee or control the disclosure and commercial use of
such Intellectual Property in a manner that protects the Parties’ interests in such Intellectual Property that might have commercial applications in the Field. ERS shall, for so long as such a Joint Development Plan is in effect but subject to
any confidentiality obligations ERS has to third parties, provide Stepan a monthly update on Products or Derivatives arising from its own development efforts, or those efforts resulting from such contractual arrangements, that are relevant to the
Joint Development Activity Field(s) in effect at the time of such update. 

  
 -7-

  3.4. Failure to Agree on a Joint Development Plan. If the Parties are unable to
agree upon a Joint Development Plan within thirty (30) days of the date of a Joint Development Notice, then either Party may escalate the dispute or disagreement with respect to Milestones and such other terms as may be in dispute or are
subject to disagreement in accordance with the procedures set forth in Section 13.1, in which case the Parties’ escalation representatives shall, over a period not to exceed thirty (30) days, use good faith efforts to resolve
the dispute or disagreement and to establish Milestones and other commercial terms with respect to such Joint Development Activity that are mutually acceptable to the Parties, and the Parties shall document all aspects of the Joint Development Plan
upon which the Parties are able to agree. The Parties shall cease all activities with respect to the proposed Joint Development Activity pending resolution of such dispute or disagreement. 

 
 If the Parties are unable to agree upon any Milestones or any
other commercial terms to be applicable to a Joint Development Plan through the escalation process set forth in Section 13.1 within the thirty (30) day period for escalation, then, unless the Parties agree to extend the period to
resolve the dispute or disagreement, Stepan shall 
  

(a) elect to abandon the proposed Joint Development Activity (in which case Section 6.4 shall apply), or 

 
 (b) submit the dispute with respect to Milestones and/or
other commercial terms regarding the proposed Joint Development Activity to binding arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, which submission shall include all terms of the
Joint Development Plan to which the Parties were able to agree and shall identify those terms of the Joint Development Plan that are in dispute. 
  

The arbitration shall be heard and determined by a panel of three (3) arbitrators, each of whom shall be a neutral and disinterested
commercial attorney having reasonable experience and qualifications to arbitrate a dispute hereunder. Each Party shall choose one (1) arbitrator, with the third arbitrator chosen by agreement of the two (2) arbitrators chosen by the
Parties. In the event the two (2) arbitrators chosen by the Parties cannot agree on a third arbitrator, such third arbitrator shall be selected by the American Arbitration Association. The decision of a majority of the arbitrators shall be
final and binding on the Parties. The arbitration proceeding shall occur in Chicago, Illinois, each Party shall bear its own costs relating to such arbitration, and the Parties shall equally share the arbitrators’ fees and expenses. The
resolution of the arbitrators shall be final and binding on the Parties, without right of appeal. Notwithstanding the foregoing, in no event shall any arbitration award provide a remedy beyond those permitted under this Agreement, and any award
providing a remedy beyond those permitted under this Agreement shall not be confirmed, no presumption of validity shall attach, and such award shall be vacated. Materials exchanged or submitted under the arbitration and other information related to
the arbitration proceeding shall be Confidential Information of the disclosing Party. 
  
 The arbitration panel shall, utilizing data and information provided by ERS and Stepan, 
  

	 	(i)	 	 assess the Parties’ disputed positions regarding the resources, efforts and scope of the proposed Joint Development Activity under the proposed
Joint Development 

  
 -8-

	 	
Plan and the Parties’ disputed proposed Milestones and commercial terms with respect thereto in light of the size and scope of the market opportunity in connection with such Joint
Development Activity and in light of those terms of the Joint Development Plan that the Parties have agreed to and are not in dispute, and 

  

	 	(ii)	 	establish a set of terms to be included in the Joint Development Plan solely with respect to those terms in dispute between the Parties, which terms shall be
appropriate, equitable, and commercially feasible in light of: 

  

	 	(A)	 	the size and scope of the market opportunity in connection with such Joint Development Activity; 

  

	 	(B)	 	the exclusivity that applies to Joint Development Plans hereunder; and 

 

	 	(C)	 	the technological, resource, capital and other commercial and technical capabilities and characteristics of the Parties. 

 
 Upon establishment of such terms with respect to the matters
in dispute between the Parties by the arbitration panel, such established terms shall be binding on the Parties and shall be added to a Joint Development Plan entered into by the Parties. 
  
 In the event the arbitration panel establishes a set of terms to be included in the Joint Development Plan
which has the effect of reducing the scope of the Joint Development Activity Field as compared to the original scope of the Joint Development Activity Field set forth in the Development Notice, the Parties agree that the portion of the Joint
Development Activity Field that has been withdrawn from the Joint Development Plan shall not be deemed to have been abandoned by Stepan except as set forth below. The arbitration panel shall, utilizing data and information provided by ERS and
Stepan: 
  

	 	(i)	 	determine the scope of the Joint Development Activity Field that has been withdrawn, the resources and capital needed to conduct a Joint Development Activity with
respect to that withdrawn scope portion, and the size and scope of the market opportunity associated with that withdrawn scope portion; and 

  

	 	(ii)	 	calculate a reasonable, one-time fee, payable by Stepan to ERS at Stepan’s election, to reserve Stepan’s exclusive right to establish a Joint Development
Activity under Section 3.1, on such withdrawn scope portion of the Joint Development Activity Field (the “Joint Development Reservation Fee”). The arbitration panel shall establish the time period during which
Stepan’s exclusive right to establish a Joint Development Activity will be reserved (“Joint Development Reservation Period”), which in no event shall be less than one (1) year or more than three (3) years in duration.

  
 In calculating the Joint
Development Reservation Fee, the arbitration panel shall consider, among other things and in addition to the information provided by the Parties to the arbitration panel: (A) the likelihood that a Joint Development Plan directed to the
withdrawn scope portion of the Joint Development Activity Field will result in a successful 

  
 -9-

 
commercialization of a Product, Developed ERS Product or Derivative in the withdrawn scope portion of the Joint Development Activity Field and (B) the duration of the Joint Development
Reservation Period. If Stepan elects not to pay the Joint Development Reservation Fee, the withdrawn scope portion of the Joint Development Activity Field shall be deemed to have been abandoned by Stepan (in which case Section 6.4 shall
apply). 
  
  3.5. Failure to Meet Milestones by
Stepan. If Stepan fails to meet any Milestone under a Joint Development Plan within thirty (30) days after receipt of notice thereof from ERS: 
   

(a) Stepan may escalate the issue for discussion and escalation in accordance with the procedures set forth in Section 13.1,
in which case the Parties’ escalation representatives shall engage in good faith discussion as to whether the Milestones should be equitably adjusted due to changed circumstances or other factors outside the Parties’ control and how
exclusivity should be adjusted; or 
  
 (b) Stepan
may elect, in its sole discretion, during the period from the time such notice is given by ERS until the earlier of thirty (30) days thereafter and such time as the Parties terminate attempts to address the failure pursuant to the procedures
set forth in Section 13.1, to pay the applicable Exclusivity Fee(s) for the Joint Development Plan, in which case the exclusivity under the Joint Development Plan for the applicable Joint Development Activity and the Joint Development
Activity Field thereunder shall remain in effect for a period of one (1) year from the date the Milestone was missed. If the Parties are unable to agree to an adjustment to the Milestones or other aspects of the Joint Development Plan through
the procedures set forth in Section 13.1 and Stepan does not elect to pay the Exclusivity Fee in accordance with the foregoing, ERS may terminate the Joint Development Plan as set forth in Section 11.3.  

 
  3.6. Failure to Meet Milestones by ERS. If ERS
fails to meet any Milestone under a Joint Development Plan within thirty (30) days after receipt of notice thereof from Stepan, ERS may escalate the issue for discussion and escalation in accordance with the procedures set forth in
Section 13.1, in which case the Parties’ escalation representatives shall engage in good faith discussion as to whether the Milestones should be equitably adjusted due to changed circumstances or other factors outside the
Parties’ control and how exclusivity should be adjusted. If the Parties are unable to agree to an adjustment to the Milestones or other aspects of the Joint Development Plan through the procedures set forth in Section 13.1 after
escalation in accordance with the foregoing, Stepan may elect, in its sole discretion, to either terminate the applicable Joint Development Plan as set forth in Section 11.4 or to continue to perform under the applicable Joint
Development Plan, in which case: 
   
 (a) ERS
shall use commercially reasonable efforts to remedy the failure to meet the applicable Milestone and to meet the other Milestones for which it is responsible; 
  

(b) subject to the last sentence of this Section 3.6, the exclusivity with respect to Joint Development Activities thereunder
pursuant to Section 3.3 shall remain in effect until the Milestone is remedied by ERS; and 
  

(c) the exclusivity with respect to any Derivative that has been commercialized prior to the Milestone failure by ERS or in such extended
period of exclusivity shall remain in effect until the Milestone is remedied by ERS, and (d) the obligations on Stepan to meet Milestones for which it is responsible shall be suspended until the milestone is remedied by ERS. 

  
 -10-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

If ERS fails to remedy the Milestone [***] pursuant to clause (b) of the preceding sentence, then: 

 

	 	(i)	 	if Stepan has not successfully commercialized a Derivative as part of the applicable Joint Development Activity, the exclusivity with respect to the applicable Joint
Development Activity and the applicable Joint Development Activity Field under Section 3.3 shall terminate and convert to non-exclusive for the Parties and the provisions of Section 6.5 shall apply; or

  

	 	(ii)	 	if Stepan has commercialized a Derivative as part of the applicable Joint Development Activity, Stepan shall elect either (A) to continue to perform under the
applicable Joint Development Activity on an exclusive basis, in which case the Milestones that ERS has failed to meet shall be modified to reflect the actual validated performance of ERS and the applicable Joint Development Plan shall continue in
accordance with its terms or until a commercial agreement with respect thereto is entered into by the Parties, or (B) to terminate the exclusivity with respect to the Joint Development Activity, in which case the exclusivity with respect to the
applicable Joint Development Activity and the applicable Joint Development Activity Field under Section 3.3 shall terminate and convert to non-exclusive for the Parties and the provisions of Section 6.5 shall apply.

  
  3.7. Tracking and Adjustment
of Milestones. The Parties shall track the Milestones routinely to ensure mutually-beneficial progress and the Parties shall, through the Executive Team, assess updates to the Milestones semi-annually (or more frequently if mutually agreed) to
enable the most effective use of resources by both Parties. 
  
 3.8. Amendments to Joint Development Plans. The Parties may, from time to time, amend any Joint Development Plan or attach new Joint Development Plans to reflect changed objectives or expected
results or to add, delete or modify Stepan Products and product categories, ERS inputs, Stepan outputs, the Parties’ respective obligations, or other details related to the Joint Development Activities. Any amendment to a Joint Development Plan
must be in writing and signed and shall be an amendment to this Agreement that is entered into in accordance with Section 14.2. 
  

3.9. Costs of Development Activities. Unless expressly set forth to the contrary in the Joint Development Plan, each Party shall
bear its own costs and expenses to conduct the Joint Development Activities. 
  
 3.10. Use of Subcontractors and Consultants. Each Party may use subcontractors or consultants to engage in the Joint Development Activities on such Party’s behalf. Without limiting anything
herein, each Party shall bind its subcontractors and consultants to obligations of confidentiality and transfer and ownership of Intellectual Property (including transfers thereof as necessary to effect the ownership and licensing of Intellectual
Property between the Parties 

  
 -11-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
 
hereunder) consistent with those specified in this Agreement and such other applicable obligations that are consistent with those set forth herein with respect to the Parties. Each Party shall be
liable for the acts and omissions of its subcontractors and consultants related to this Agreement. 
  

4. Commercial Agreement. 
  

4.1. Commercial Agreement and Value Share. In connection with each Joint Development Plan, the Parties shall negotiate various
commercial terms and/or agreements for the supply from ERS to Stepan of Products and/or Developed ERS Products in connection with the Joint Development Activities under such Joint Development Plan and for the sharing of profits resulting from sales
of Products, Developed ERS Products, or Derivatives to customers. Each Joint Development Plan shall include the pricing and profit share approach and methodology to be included in such commercial agreement, which pricing and profit share approach
shall include: 
  

	 	(a)	 	[***] 

   

	 	(b)	 	[***]; and 

  

(c) customary audit rights and payment terms related to pricing and profit sharing; provided that the Parties may convert any value
sharing or profit sharing mechanism to a straight price calculation at any time in the future upon mutual agreement. 
  

The Parties agree that the basis for the pricing and profit share approach for each Joint Development Plan shall be based on [***] may be adjusted upon
mutual agreement to recognize inordinate expenses, resources, efforts, or other factors. The Parties shall not be required to enter into a separate commercial agreement for each Joint Development Plan, but may enter into a master commercial
agreement with a framework to accommodate distinct or separate products, pricing, value share, and other commercial details for each Joint Development Plan. 
  

4.2. Commercial Exclusivity. With respect to any Product, Developed ERS Product or Derivative that has been commercialized in
connection with a Joint Development Activity and for so long as the applicable Joint Development Plan remains in effect, (a) ERS shall not knowingly supply Product or Developed ERS Product to any third party within the applicable Joint
Development Activity Field except in the context of an existing or future contractual relationship of the type exempted from the exclusivity requirements of Section 3.3 for the supply of non-commercial quantities of such Product,
Developed ERS Product or Derivative for research purposes only, and (b) Stepan shall source all of its requirements for such Products and Developed ERS Products from ERS. If ERS becomes aware that any third party to which ERS has supplied
Product or Developed ERS Product has made use of such Product or Developed ERS Product within the applicable Joint Development Activity Field, ERS shall take all commercially reasonable actions to terminate supply to such third party or to otherwise
prevent such use being made in a similar manner in the future. 

  
 -12-

 5. Program Management. 

 
 5.1. Composition of Executive Team. The Parties’
respective members of the Executive Team are John Venegoni and Frank Pacholec for Stepan and Andy Shafer and Steve DiBiase for ERS. Each Party may change its designated members in the Executive Team by notifying the other Party in writing, and each
Party shall promptly fill any vacancy on the Executive Team. Each member of the Executive Team shall have an appropriate level of education, training, and experience to effectively carry out his or her respective responsibilities in connection with
the Executive Team. 
  
 5.2. Meetings and
Responsibilities of Executive Team. The Executive Team shall meet periodically, but in no event less frequently than once every six (6) months, to decide on all strategic decisions with respect to the Joint Development Activities. Each
meeting of the Executive Team shall be attended by at least one (1) representative of each Party, but all decisions of the Executive Team shall be made in accordance with Section 5.3. Within two (2) weeks of each meeting of the
Executive Team, a selected representative of the Executive Team shall distribute a written summary of the meeting and any decisions made or issues identified to the Parties. The Executive Team shall determine which Products and Derivatives will be
commercialized and shall also be responsible for material modifications to the Joint Development Activities, including any formal amendment thereto. The Executive Team shall work together in good faith to resolve any issue identified by, or brought
to the attention of, the Executive Team. 
  
 5.3.
Decisions of Executive Team. The Executive Team shall make its decisions by unanimous vote of all of its members, and such decisions shall be documented in writing. Members of the Executive Team may participate in, and vote at, meetings in
person or by telephone. For any matters that the Parties are unable to agree upon by unanimous decision of the Executive Team, either Party may submit such matter for resolution in accordance with Section 13.1. 

 
 5.4. Records. Each Party shall keep and maintain
adequate records and reports to enable it to furnish the Executive Team with complete and accurate information regarding the conduct of the Joint Development Activities as reasonably requested by the Executive Team. 

 
 5.5. Technical Coordinators. Each Party’s initial
Technical Coordinator for applicable Joint Development Activities shall be specified in each corresponding Joint Development Plan. Each Party may change its Technical Coordinator under a Joint Development Plan at any time by notifying the other
Party in writing. The Technical Coordinator shall be authorized by each Party to: (a) represent that Party in discussions regarding all technical matters related to performance of the Joint Development Activities and the day-to-day operations
under the corresponding Joint Development Plan; (b) coordinate the exchange of Confidential Information; and (c) report to the Executive Team on the status of the Joint Development Activities and the implementation and execution of the
applicable Joint Development Plan. 
  
 6. Intellectual Property
Rights. 
  
 6.1. Existing Intellectual
Property. 

  
 -13-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

(a) Existing ERS Intellectual Property. ERS shall remain the sole and exclusive owner of all right, title and
interest in and to, all of the Existing ERS Intellectual Property. ERS hereby grants to Stepan an [***]. The [***] license set forth above shall not limit ERS’s own use of, or exercise of rights with respect to, Existing ERS Intellectual
Property (i) in accordance with its activities hereunder, or (ii) outside of the scope of the license set forth above. 
   

(b) Existing Stepan Intellectual Property. Stepan shall remain the sole and exclusive owner of all right, title and
interest in and to, all of the Existing Stepan Intellectual Property. Stepan hereby grants to ERS an [***]. The [***] license set forth above shall not limit Stepan’s own use of, or exercise of rights with respect to, Existing Stepan
Intellectual Property (i) in accordance with its activities hereunder, or (ii) outside of the scope of the license set forth above. 
  

6.2. ERS Owned Developed Intellectual Property. 

 
 (a) ERS Owned. ERS shall own all
right, title and interest in and to [***] by the Parties. 
  
 (b) Transfer of Ownership. Stepan hereby irrevocably transfers and assigns to ERS any and all of its right, title, and interest in and to such [***] owned by ERS to the fullest extent permitted by
applicable law. 
  
 (c)
License. ERS hereby grants to Stepan: 
  
 (i) an [***] in each case solely as necessary to perform its obligations and activities under this Agreement, including Initial Screening and Joint Development Activities; and 

 
  (ii) a [***]. 

 
 The [***] license set forth above in
Section 6.2(c)(i) shall not limit ERS’s own use of, or exercise of rights with respect to, Existing ERS Intellectual Property (i) in accordance with its activities hereunder, or (ii) outside of the scope of the license set
forth above. Notwithstanding the fact that Non-Field Applications Intellectual Property is intended to apply to applications outside of the Field (as may be modified during and after the Initial Screening Phase in the event of Stepan’s
abandonment and to account for the formation of Joint Development Activity Fields as set forth herein) only, the foregoing licenses under Non-Field Applications Intellectual Property set forth in this Section 6.2(c) shall apply if and to
the extent any such Non-Field Applications Intellectual Property applies to any applications within the Field, and such licenses shall apply to use of such Non-Field Applications Intellectual Property solely within the Field. 

 
 6.3. Stepan Owned Developed Intellectual Property.

  
 (a) Stepan Owned. Stepan
shall own all right, title and interest in and to all [***]. 

  
 -14-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

(b) Transfer of Ownership. ERS hereby irrevocably transfers and assigns to Stepan any and all of its right, title,
and interest in and to [***] to the fullest extent permitted by applicable law. 
  
 (c) License. Stepan hereby grants to ERS: 
  

(i) an [***] as necessary to perform its obligations and activities under this Agreement, including Initial Screening and
Joint Development Activities; and 
  

(ii) an [***]; and 
  

(iii) a [***]. 
  

The [***] license set forth above in Section 6.2(c)(i) shall not limit Stepan’s own use of, or exercise of rights with
respect to, Existing Stepan Intellectual Property (i) in accordance with its activities hereunder, or (ii) outside of the scope of the license set forth above. 

 
 6.4. Intellectual Property in Abandoned Portions of
Field. If, (a) during the Initial Screening Phase or within thirty (30) days of the completion of the Initial Screening Phase, Stepan elects not to pursue a Joint Development Activity with respect to any portion of the Field as set
forth in Section 2.4 or if Stepan fails to meet any Screening Milestones as set forth in Section 2.3, or (b) if Stepan elects to abandon a proposed Joint Development Plan or elects not to pay a Joint Development
Reservation Fee as set forth in Section 3.4 then, notwithstanding anything herein to the contrary and without limiting the licenses granted in Section 6.3(c)(ii), Stepan hereby grants, and shall grant, to ERS an [***].

  
 6.5. Intellectual Property upon Failure of ERS
to Meet Milestones. Upon the conversion of a Joint Development Activity to non-exclusive as set forth in the last sentence of Section 3.6, 
  

(a) Stepan, in its sole discretion, may elect to cease activities with respect to such Joint Development Activity, in
which case any Derivatives and Applications Intellectual Property developed during the Initial Screening Phase and pursuant to such Joint Development Activity prior to Stepan’s election to cease activities shall be treated in accordance with
Section 6.4, or 
  
 (b)
if Stepan, in its sole discretion elects not to cease activities with respect to such Joint Development Activity in some portion of the Joint Development Activity Field, and Stepan continues to perform inside the applicable Joint Development
Activity Field, then: 
  

	 	(i)	 	ERS hereby grants, and shall grant, to Stepan a [***]; 

  

	 	(ii)	 	Stepan hereby grants, and shall grant, to ERS a [***]; 

  
 -15-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

	 	(iii)	 	ERS shall use commercially reasonable efforts to supply Product or Developed ERS Product to Stepan on mutually agreed upon acceptable and non-exclusive commercial terms
consistent with the provisions as set forth in Section 4.1 with respect to the sale of any Products, Developed ERS Products and Derivatives hereunder. Without limiting Section 3.6, if ERS is unable to meet any Milestone
related to supply of Products or Developed ERS Products, ERS will use commercially reasonable best efforts to remedy any supply disruption as promptly as possible, including through the use of alternative toll manufacturers or suppliers; and

  

	 	(iv)	 	ERS hereby grants, and shall grant, to Stepan an [***]. 

  

Notwithstanding the fact that Non-Field Applications Intellectual Property is intended to apply to applications outside of the Field (as may be modified
during and after the Initial Screening Phase in the event of Stepan’s abandonment and to account for the formation of Joint Development Activity Fields as set forth herein) only, the foregoing licenses under Non-Field Applications Intellectual
Property set forth in Section 6.5(b)(i) and Section 6.5(b)(iv) shall apply if and to the extent any such Non-Field Applications Intellectual Property applies to any applications within the applicable Joint Development
Activity Field, and such licenses shall apply to use of such Non-Field Applications Intellectual Property solely within the applicable Joint Development Activity Field. 

 
 6.6 Certain Post-Termination Licenses and Transfers.

  
 (a) Termination by ERS for Stepan’s
Failure to Meet Milestones. If ERS terminates a Joint Development Plan pursuant to Section 11.3 due to Stepan’s failure to meet a Milestone, then 

 

	 	(i)	 	Stepan hereby grants, and shall grant, to ERS a [***]; and 

  

	 	(ii)	 	ERS hereby grants, and shall grant, to Stepan a [***]; 

  

	 	(iii)	 	With respect to the use and sale by Stepan of any Products, Developed ERS Products, and/or Derivatives under Section 6.6(a)(ii), Stepan shall source all of
its requirements for such Products and/or Developed ERS Products from ERS; provided, however, that if ERS is unable to supply all or a portion of Stepan’s requirements for such Products and/or Developed ERS Products, Stepan may
source that portion of its requirements for such Products and/or Developed ERS Products that ERS is unable to supply from a third party, and may enter into a contractual arrangements with any such third party provided that such contractual
arrangements shall not have terms of more than one (1) year in duration. ERS will use commercially reasonable efforts to supply Product or Developed ERS Product to Stepan on mutually agreed upon acceptable commercial terms consistent with the
provisions as set forth in Section 4.1 and Section 4.2 with respect to the sale of any Products, Developed ERS Products, and Derivatives hereunder (provided that subsection (a) of Section 4.2 with respect to
limitations on ERS’s supply of Products to third parties shall not apply); and 

  
 -16-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

	 	(iv)	 	ERS hereby grants, and shall grant, to Stepan an [***]. 

  

Notwithstanding the fact that Non-Field Applications Intellectual Property is intended to apply to applications outside of the Field (as
may be modified during and after the Initial Screening Phase in the event of Stepan’s abandonment and to account for the formation of Joint Development Activity Fields as set forth herein) only, the foregoing licenses under Non-Field
Applications Intellectual Property set forth in Section 6.6(a)(ii) and Section 6.6(a)(iv) shall apply if and to the extent any such Non-Field Applications Intellectual Property applies to any applications within the
applicable Joint Development Activity Field, and such licenses shall apply to use of such Non-Field Applications Intellectual Property solely within the applicable Joint Development Activity Field. 

 
 (b) Stepan Elective Termination. If a Joint
Development Plan is terminated by Stepan pursuant to Section 11.4, then Stepan shall grant to ERS an [***] such applicable Joint Development Activity Field. 

 
 6.7 Disclosure; Further Assurances. Each Party shall:
(a) disclose promptly in writing to the other Party the existence of any Developed Intellectual Property (including any related data) as it is discovered, learned, created, or developed and, at the other Party’s request, disclose such
information and detail regarding such Developed Intellectual Property as reasonably requested; (b) cooperate with and assist the other Party, at the other Party’s expense, to apply for, and to execute, any applications and/or assignments
reasonably necessary to obtain, maintain, enforce, or protect any patent, copyright, trademark or other protection for Intellectual Property in such other Party’s name (consistent with the ownership provisions set forth above) as such other
Party reasonably requests, and require its employees and contractors who have developed any Developed Intellectual Property to do the same (including in connection with the execution of any assignments from authors, creators, developers, or
inventors of any Developed Intellectual Property); and (c) treat all Developed Intellectual Property owned by the other Party as Confidential Information of such other Party. 

 
 6.8 Rights to File; Abandonment. Each Party shall have
the exclusive right at such Party’s expense to file, prosecute, issue, maintain, license (to the extent not inconsistent with this Agreement) and defend all patent applications and patents, throughout the world, containing solely that
Party’s rights in any Developed Intellectual Property owned by that Party; provided that each Party shall disclose to the other Party any patent applications for Developed Intellectual Property developed hereunder prior and shall give
such other Party a reasonable opportunity to review, comment and edit such applications. The Parties shall coordinate to minimize the overlap of claims for Non-Field Applications Intellectual Property and claims for Derivatives and Applications
Intellectual Property in the same patent application, with the goal of separating patent applications for Non-Field Applications Intellectual Property from patent applications for Derivatives and Applications Intellectual Property with no claims of
one type of Developed Intellectual Property being included in a patent application embodying the other type of Developed Intellectual Property. If either Party does not desire to maintain its interest in a patent or patent application derived from
Developed Intellectual Property, it will offer to the other Party the application or patent in question with the right prosecute and maintain the patent application or patent solely for such other Party’s own benefit and at such other
Party’s expense, in which case such Party shall assign all of its right, title and interest in and to such patent application or 

  
 -17-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
 
patent to such other Party and takes such other acts (including executing such other documents and providing such other information) as reasonably requested by such other Party to effectuate the
foregoing. 
  
 6.9 No Obligation to License;
Reserved Rights. Except as expressly set forth herein, (a) nothing in this Agreement shall be construed to require either Party to disclose or license to the other Party, or grant the other Party access to, any of its Intellectual Property,
including, without limitation, any of its Developed Intellectual Property, and (b) each Party expressly reserves all rights in and to its Intellectual Property, including, without limitation, any of its Developed Intellectual Property.

  
  6.10 Royalties and Royalty Payments.
If either Party sells any [***] pursuant to Section 6.5(b) or Section 6.6(a), under any patents or patent applications included in Derivatives and Applications Intellectual Property, in the case of Stepan, or Product
Intellectual Property or Non-Field Applications Intellectual Property, in the case of ERS, that Party shall pay the other Party a royalty in an amount set forth in the applicable Joint Development Plan (based on a percentage of EBIT) on all sales of
such [***] in the applicable Joint Development Activity Field in each agreed-upon royalty period until the expiration of the last such patent to expire or until the final rejection of the last such patent application outstanding (whichever is
later); provided that Stepan shall not be required to pay any such royalty if Stepan purchases from ERS the applicable Products or Developed ERS Products utilized to make [***]. Each Party shall make royalty payments to the other Party due
hereunder within [***] made and shall provide with such payments to the other Party a sales and royalty report with reasonable supporting detail regarding the sales and EBIT on which such royalty. Each Party shall have the right, through its
designated independent auditor, no more than once in any period of twelve (12) consecutive months and upon at least fifteen (15) days advance notice to the other Party, to review the books and records of such other Party related to such
sales of covered [***] and corresponding EBIT for the sole purpose of verifying the accuracy of royalty payments by such other Party hereunder. If any such audit discovers an underpayment of royalties hereunder, the auditing Party shall provide
notice thereof to the audited Party and the audited Party shall pay any undisputed underpaid royalties hereunder within forty-five (45) days of such notice. If the audited Party disputes the results of any audit hereunder, the Parties shall
address such dispute through the procedures specified in Section 13.1. The royalty amount for any license identified herein as royalty-bearing shall be set forth in the applicable Joint Development Plan (based on a percentage of EBIT for
the applicable [***]). 
   
 7.
Confidential Information. 
  
 7.1.
Duty of Confidentiality. Each Party acknowledges that (a) it has received Confidential Information of the other Party prior to the Effective Date under a prior confidentiality agreement and in furtherance of entering into this Agreement,
and (b) it may acquire Confidential Information of the other Party in connection with its performance of its obligations set forth in this Agreement. Any Party disclosing Confidential Information hereunder shall clearly mark such Confidential
Information using words such as “confidential” or “proprietary” or other words clearly indicating its confidential nature and, with respect to Confidential Information disclosed orally, shall provide a written summary of such
Confidential 

  
 -18-

 
Information and confirm the confidential nature of any such Confidential Information in writing within thirty (30) days of its disclosure. During the term of this agreement and for five
(5) years after the Term, each Party shall hold all Confidential Information of the other Party in confidence, using the same degree of care to prevent unauthorized disclosure or access that it uses with its own confidential information of
similar type (but in no event using less than a reasonable degree of care), and shall not disclose such Confidential Information to others, allow others to access it, or use it in any way, commercially or otherwise, except in furtherance of
performing its obligations under this Agreement; provided, however, that each Party may disclose Confidential Information to its Affiliates and to its and their attorneys, accountants and other confidential advisors who need to know
such information for the purpose of assisting such Party in connection with the transactions contemplated herein or the subject matter hereof that are bound by a duty of confidentiality of even scope herewith and to bona fide potential investors,
acquirers, or lenders that are bound by confidentiality agreements of even scope herewith. Any Confidential Information transmitted to an employee or affiliate of the receiving Party shall be considered as transmitted to the receiving Party. Any
information disclosed by an employee or affiliate of the disclosing Party shall be considered to be disclosed by the disclosing Party. 
  

7.2. Exclusions. Confidential Information shall not include information if and to the extent the receiving Party can prove such
information: 
  

	 	(a)	 	is or becomes known to the public other than by disclosure by the receiving Party in violation of this Agreement; 

 

	 	(b)	 	was known to the receiving Party previously, without a duty of confidentiality and as evidenced by tangible records of such knowledge; 

 

	 	(c)	 	was independently developed by the receiving Party outside of this Agreement and the Services and without access to any Confidential Information of the disclosing
Party; or 

  

	 	(d)	 	was rightfully obtained by the receiving Party from third parties without a duty of confidentiality. 

 
 7.3. Permitted Disclosure. If a Party is requested to
disclose all or any part of any Confidential Information of the other Party under a discovery request, a subpoena, or inquiry issued by a court of competent jurisdiction or by a judicial, administrative, regulatory or governmental agency or
legislative body or committee, the Party so requested shall, to the extent practicable and subject to applicable laws, give prompt written notice of such request to such other Party and shall give such other Party the opportunity to seek an
appropriate confidentiality agreement, protective order or modification of any disclosure or otherwise intervene, prevent, delay or otherwise affect the response to such request and the receiving Party shall, at such other Party’s expense,
cooperate in such efforts. 
  
 7.4. Return of
Confidential Information. Upon termination or expiration of this Agreement, or at any time with respect to particular Confidential Information not required by the receiving Party to perform such receiving Party’s obligations under this
Agreement, upon request by the disclosing Party the receiving Party shall (a) return to the disclosing Party all Confidential 

  
 -19-

 
Information disclosed by such disclosing Party hereunder and all copies thereof that are in the receiving Party’s possession or control, and (b) use commercially reasonable efforts to
delete from its computers, databases, and servers any electronic copies of all such Confidential Information; provided, however, that (i) each Party may retain one (1) copy of any Confidential Information for its internal
legal files or the files of its outside counsel, and (ii) the foregoing shall not require a receiving Party to return any Confidential Information that is integrated with any Developed Intellectual Property owned by such receiving Party.

  
 7.5. Termination of Prior Confidentiality
Agreement. The Parties hereby terminate the prior Confidentiality Agreement entered into by the Parties dated as of October 6, 2009, which Confidentiality Agreement is hereby superseded and replaced in its entirety by this Agreement and the
confidentiality provisions set forth herein. The Parties acknowledge and agree that any confidential or proprietary information provided under such Confidentiality Agreement is Confidential Information for purposes of, and subject to, this
Agreement. 
  
 7.6. Publicity. Neither Party
shall, without the prior written consent of the other Party or except as otherwise expressly permitted in a Joint Development Plan: (a) use in advertising, publicity, or otherwise in connection with any product developed hereunder, any trade
name, trademark, trade device, service mark, or symbol owned by the other Party; or (b) represent, either directly or indirectly, that any product or service of the other Party is a product or service of such Party, or vice versa. 

  
 7.7. Disclosure of Relationship, Press
Releases and Marketing Plan. Notwithstanding Section 7.6 or anything else to the contrary in this Agreement, (a) each Party shall have the right to disclose the existence of the Parties’ relationship under this Agreement,
(b) the Parties shall jointly develop and issue a press release relating to this Agreement and their relationship hereunder promptly within thirty (30) days after execution of the Agreement, and (c) the Parties shall jointly develop,
in connection with any Joint Development Plan, an agreed marketing plan that includes the use of the Parties’ names and identification of the Parties’ respective products or contributions with respect to the Products developed
hereunder.  
  
 8. Representations and Warranties of the
Parties. 
  
 8.1 Representations and
Warranties by both Parties. Each Party hereby represents and warrants to the other that such Party has full power and authority to enter into this Agreement, to carry out such Party’s obligations hereunder, and to grant the rights set forth
herein, and that the provisions set forth in this Agreement constitute legal, valid, and binding obligations of such Party enforceable against such Party in accordance with their terms, subject to bankruptcy, insolvency, reorganization and other
laws affecting creditors’ rights generally, and with regard to equitable remedies, to the discretion of the court before which proceedings to obtain such remedies may be pending. 
  
 8.2 Representations and Warranties by ERS. ERS hereby represents and warrants to Stepan that ERS has not
previously granted and will not grant to any third party any rights in conflict with any licenses granted to Stepan hereunder; no consent, license, release, approval or immunity is required from any third party for ERS to enter into and perform its
obligations under 

  
 -20-

 
this Agreement except for any consents, licenses, releases, approvals or immunities which have been obtained. In the event of any material breach of the foregoing representation and warranty as
it relates to any existing or future licenses granted by ERS to any third party, including but not limited to, consultants, laboratories, universities, research centers, research and development contractors, and other contractors, Stepan will grant
ERS an opportunity, after receipt of any notice from Stepan, ninety (90) days to cure such breach with such third party. In the event the breach remains uncured after ninety (90) days, Stepan reserves the right to proceed directly to a
court with competent jurisdiction. The Parties agree that the Court may determine in its sole discretion, an appropriate remedy or remedies for an ERS breach which may include, but not be limited to, in whole or in part, (i) reformation of
contract, (ii) appropriate money damages, including any costs, losses, or expenses (including reasonable attorney fees incurred), and/or (iii) any equitable or other remedy as the Court may determine in its sole discretion as being
appropriate to remedy the breach, and the Parties hereby waive any right to contest the authority of such Court to adopt any such remedy or remedies. 
  

9. Indemnification 
  

9.1. Indemnification by Stepan. Stepan shall defend, indemnify and hold harmless ERS and its Affiliates and its and their
officers, directors, employees, agents and representatives from all claims, judgments, damages, liabilities, actions, demands, costs, expenses, or losses, including, without limitation, reasonable attorneys’ fees and costs, to the extent
resulting from, arising out of, or in connection with, any third party claim arising out of or related to: (a) any claim of the infringement or misappropriation of any third party Intellectual Property rights related to any Derivative
developed, provided or sold by Stepan (but excluding any Product provided by ERS to Stepan) or its method of manufacture or any materials provided by Stepan in connection with the Joint Development Activities; (b) any gross negligence or
willful misconduct of Stepan; or (c) any violation of any statute, ordinance, or regulation by Stepan. 
  

9.2. Indemnification by ERS. ERS shall defend, indemnify and hold harmless Stepan and its Affiliates and its and their
officers, directors, employees, agents and representatives from all claims, judgments, damages, liabilities, actions, demands, costs, expenses, or losses, including, without limitation, reasonable attorneys’ fees and costs, to the extent
resulting from, arising out of, or in connection with, any third party claim arising out of or related to: (a) any claim of the infringement or misappropriation of any third party Intellectual Property rights related to any Product or Developed
ERS Product or its method of manufacture or any materials provided by ERS in connection with the Joint Development Activities; (b) any gross negligence or willful misconduct of ERS; or (c) any violation of any statute, ordinance, or
regulation by ERS. 
  
 9.3.
Indemnification Procedures. A Party seeking indemnification under this Article 9 shall promptly notify the other Party in writing of any action, claim or liability in respect of which such Party or any related indemnified party
intends to claim such indemnification. The Party seeking indemnification shall permit, and shall cause its related indemnified parties to permit, the indemnifying Party to settle any such action, claim or liability and agrees to the control of such
defense or settlement by the indemnifying Party; provided, however, that such settlement does not adversely affect the indemnified Party’s (or any related indemnified party’s)

  
 -21-

 
rights hereunder or impose any obligations on the indemnified Party or any related indemnified party in addition to those set forth herein. The indemnified Party shall not settle any such action,
claim or liability without the prior written consent of the indemnifying Party, and the indemnifying Party shall not be responsible for any attorneys’ fees or other costs incurred other than as provided herein. The indemnified Party and its
related indemnified parties and their respective employees and agents, shall cooperate fully with the indemnifying Party and its legal representatives in the investigation and defense of any action, claim or liability covered by this Article
9. An indemnified Party shall have the right, but not the obligation, to be represented by counsel of its own selection and at its own expense. 
  

9.4. Mitigation. Each Party shall use reasonable commercial efforts to mitigate any damages incurred by it on account of a third
party claim subject to indemnification hereunder. 
  

9.5. Insurance. Each Party shall maintain comprehensive general liability insurance, including products liability and contractual
liability coverage, in an amount and for a time period that will cover the liability assumed by that Party under this Agreement. Each Party shall provide the other with a certificate of insurance evidencing the existence of these coverages upon
request. 
  
 10. Limitations of Liability and Disclaimers.

  
 10.1. Exclusion of Certain Damages. IN NO
EVENT SHALL EITHER PARTY OR ITS AFFILIATES OR ITS OR THEIR RESPECTIVE SHAREHOLDERS, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, SUB-CONTRACTORS, REPRESENTATIVES, MEMBERS, AFFILIATES, SUCCESSORS, OR ASSIGNS BE LIABLE TO THE OTHER PARTY, OR ITS
SHAREHOLDERS, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, SUB-CONTRACTORS, REPRESENTATIVES, MEMBERS, AFFILIATES, SUCCESSORS, OR ASSIGNS FOR, AND EACH PARTY HEREBY EXPRESSLY WAIVES RIGHTS TO, ANY INDIRECT, ECONOMIC, SPECIAL, INCIDENTAL, EXEMPLARY,
PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION LOST PROFITS, LOSS OF BUSINESS REVENUE OR EARNINGS, LOSS OF USE, LOSS OF DATA, LOSS OF SAVINGS, LOSSES BY REASON OF COST OF CAPITAL, OR A FAILURE TO REALIZE EXPECTED SAVINGS) DIRECTLY
OR INDIRECTLY ARISING OUT OF, OR IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED BY, THIS AGREEMENT, WHETHER OR NOT SUCH DAMAGES COULD REASONABLY BE FORESEEN OR THEIR LIKELIHOOD HAS BEEN DISCLOSED TO THE OTHER PARTY, AND REGARDLESS OF WHETHER A
CLAIM IS BASED ON CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY), VIOLATION OF ANY APPLICABLE DECEPTIVE TRADE PRACTICES ACT, OR ANY OTHER LEGAL OR EQUITABLE PRINCIPLE. 
  
 10.2. Exceptions. The exclusion of certain damages in Section 10.1 shall not apply to:
(a) the indemnification obligations set forth in Article 9; (b) liabilities (including, without limitation, any related indemnification obligations) caused by, or arising from, a Party’s gross negligence, willful misconduct,
intentional breach, fraud or violation of law; or (c) a Party’s willful or intentional disclosure of the Confidential Information of the other Party in violation of Article 6.10 that results in the loss of the confidential status of
such Confidential Information. 

  
 -22-

 10.3. Risk of Failure. Each Party recognizes and assumes the significant risks
associated with designing, developing and manufacturing Products, Developed ERS Products, Derivatives, or other products in accordance with this Agreement and the Joint Development Plan. Specifically, each Party individually assumes the risks that:
(a) neither Party will develop 

  
 -23-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
 
any products or processes that meet customer requirements or the goals of the Joint Development Plan; and (b) the market will fail to accept such products, or the market will fail to accept
such products to the level anticipated by ERS or Stepan as of the Effective Date. Although ERS and Stepan will use commercially reasonable efforts to implement and execute each Joint Development Plan, no expenditures by either Party hereunder will
be reimbursed because the development of any products or processes has been unsuccessful. EXCEPT AS OTHERWISE EXPLICITLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS TO THE OTHER PARTY ANY EXPRESS OR IMPLIED WARRANTY, INCLUDING, WITHOUT
LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARISING OUT OF ITS PERFORMANCE UNDER THIS AGREEMENT OR ITS ATTEMPTED DEVELOPMENT OF A PRODUCT OR PROCESS PURSUANT TO THIS AGREEMENT. 

 
 11. Term and Termination. 

 
 11.1. Term. This Agreement shall commence as of the
Effective Date and, unless sooner terminated as set forth below, shall expire on the date that is [***] after the Effective Date; provided, however, that the Parties shall meet promptly after the [***] anniversary of the Effective Date
to discuss renewal and may, by mutual agreement, extend the term for a mutually agreed upon renewal period at least six (6) months prior to the expiration of the initial [***] Term. Unless otherwise set forth in any other commercial agreement
entered into by the Parties, the termination of this Agreement shall not result in the termination of any such other commercial agreements (and any separate licenses to Intellectual Property granted thereunder). 

 
 11.2. Termination for Cause. Either Party may
terminate this Agreement if the other Party commits a material breach of this Agreement and fails to cure such breach, or, if such breach is incapable of cure, fails to take all commercially reasonable measures to cure such breach, within thirty
(30) days of receipt of written notice of such breach by the non-breaching Party. In addition, either Party may terminate this Agreement upon sixty (60) days advance written notice if: (a) the other Party (i) files for
bankruptcy, (ii) becomes or is declared insolvent, (iii) is the subject of any proceedings related to its liquidation, insolvency or the appointment of a receiver or similar officer for it, which proceedings are not dismissed within sixty
(60) days after their commencement, or (iv) makes an assignment of all or substantially all of its assets or properties for the benefit of its creditors; or (b) the other Party purchases, directly or indirectly, all or substantially
all of the assets of a Competitor of such Party or fifty percent (50%) or more of the stock of a Competitor of such Party, or a Competitor of the terminating Party purchases, directly or indirectly, all or substantially all of the assets of
such other Party or fifty percent (50%) or more of the stock of such other Party. 
  
 11.3. Termination of Joint Development Plan for Failure to Meet Milestones. ERS shall have the right, but not the obligation, to terminate a Joint Development Plan by notice to Stepan upon
Stepan’s failure to meet Milestones under such Joint Development Plan in the circumstances set forth in Section 3.5 and in accordance with the terms thereof. Upon such a termination of such Joint Development Plan,
Section 6.6(a) will apply with respect to certain Intellectual Property licenses and related commercialization after such termination. 

  
 -24-

 11.4. Stepan Elective Termination of Joint Development Plan. Stepan shall have the
right, but not the obligation, to terminate a Joint Development Plan on at least thirty (30) days notice to ERS if, in its reasonable determination, the Joint Development Activities thereunder are not technically feasible or commercially
viable. Upon such a termination of such Joint Development Plan, (a) the Parties shall immediately cease all Joint Development Activities with respect thereto and the exclusivity with respect to the applicable Joint Development Activity Field as
set forth in Section 3.3 and any exclusivity with respect to ERS’s supply of Products in connection therewith as set forth in Section 4.2 shall immediately cease, and (b) Section 6.6(b) will apply with
respect to certain Intellectual Property licenses after such termination. If, in the two (2) years following Stepan’s notice of such termination, ERS seeks to further develop any technology related to the Derivatives and Applications
Intellectual Property licensed to ERS pursuant to Section 6.6(b) in the Joint Development Activity Field applicable to a Joint Development Plan terminated by Stepan under this Section 11.4, ERS shall notify Stepan of such
intent and Stepan shall, at its option, have an exclusive negotiating window of thirty (30) days following such notice during which the Parties shall negotiate in good faith with respect to re-establishing a mutually agreeable Joint Development
Plan related to the previously terminated Joint Development Activities. If the Parties are unable to agree upon such a re-established Joint Development Plan or if Stepan elects not to seek to re-establish such a Joint Development Plan, ERS shall be
free to further develop such technology itself or in collaboration with one or more third parties without further obligation to Stepan. 
  

11.5. Termination for Failure to Establish a Joint Development Activity. Either Party will have the right but not the obligation,
to terminate this Agreement upon thirty (30) days prior written notice to the other Party if (a) the Parties are unable to establish a Joint Development Plan by the conclusion of the Initial Screening Phase, or (b) if sixty
(60) consecutive days have elapsed at any point during the Term during which time there has been no Joint Development Plan in effect. 
  

11.6. Survival. The obligations of the Parties under this Agreement that the Parties have expressly agreed shall survive
termination or expiration of this Agreement or that, by their nature, would continue beyond the expiration or termination of this Agreement, shall survive the expiration or termination of this Agreement for any reason. Without limiting the
generality of the foregoing, the Parties intend that the following Articles and Sections survive expiration or termination of this Agreement: Article 1, Section 6.2(a), Section 6.2(b), Section 6.2(c)(ii),
Section 6.3(a), Section 6.3(b), Section 6.3(c)(ii), Section 6.3(c)(iii), Section 6.4, Section 6.5, Section 6.6, Section 6.7, Section 6.8,
Section 6.9, Section 6.10, Article 7, Article 9, Article 10, this Section 11.6, Article 12, and Article 13 of this Agreement. 

 
 12. Non-Solicitation. 

 
 During the Term of this Agreement and for a period of one
(1) year thereafter, neither Party shall solicit the services of, hire, or engage in a business relationship with, any of the employees of the other Party for the benefit of such Party, except in responses to public, non-targeted advertisements
for employment or consultancy. Each Party understands and acknowledges that this obligation regarding solicitation is necessary and reasonable to protect the other Party’s legitimate business interests, including trade secrets, Confidential
Information, Intellectual Property, and the goodwill associated with such other Party’s business, and is provided by such Party as further inducement for such other Party to enter into this Agreement. 

  
 -25-

 13. Dispute Resolution. 

 
 13.1. Escalation. The Parties shall first attempt to
resolve any dispute relating to this Agreement within the Executive Team, the members of which shall work together in good faith to resolve any such dispute. If the Executive Team is unable to resolve any dispute after good faith efforts to do so or
after agreeing that the dispute should be resolved by senior management, the Executive Team shall escalate such dispute to one (1) senior executive of each Party, which senior executives shall promptly work together in good faith to resolve
such dispute. 
  
 13.2. Court Proceedings;
Venue. If the Parties are unable to resolve any dispute relating to this Agreement by negotiation under Section 13.1 after good faith efforts to do so except as set forth in Section 3.4, either Party may submit such
dispute to a court of competent jurisdiction in Chicago, Illinois by filing a lawsuit. ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT MUST BE BROUGHT IN THE STATE OR FEDERAL COURTS WITHIN COOK COUNTY, ILLINOIS, AND THE PARTIES
IRREVOCABLY AGREE TO THE EXCLUSIVE JURISDICTION OF, AND EXCLUSIVE VENUE IN, SUCH COURTS FOR SUCH PURPOSES AND EACH PARTY HEREBY WAIVES ANY CLAIM OR DEFENSE THAT SUCH FORUM IN SUCH COURTS IS NOT CONVENIENT OR PROPER. 

 
 13.3. Equitable Relief. Notwithstanding
Section 13.1, either Party may make a court filing or take whatever actions are necessary at any time to seek an injunction or other equitable relief where there is a likelihood of immediate and irreparable harm to its interests.

  
 14. General. 

 
 14.1. Joint Development Plans. The Joint Development
Plans, when mutually agreed upon in writing and signed by the Parties, form part of this Agreement and shall have full force and effect as if expressly set out in the body of this Agreement, and reference to this Agreement shall include the attached
Joint Development Plans. If any conflict arises between any term, condition or provision of a Joint Development Plan and any term, condition or provision of this Agreement, the applicable term, condition or provision of this Agreement shall prevail.

  
 14.2. Entire Agreement; Amendment. This
Agreement and any Joint Development Plan(s) constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof and supersede all contemporaneous oral agreements and all prior oral and written quotations,
communications, agreements, understandings of the Parties, and written or oral representations of either Party with respect to the subject matter of this Agreement, including any letter of intent, memorandum of understanding or confidentiality
agreement executed by the Parties. This Agreement shall not be amended or modified except by a written instrument executed by an authorized representative of each Party. 

 
 14.3. Notices. Any notice under this Agreement is to
be sent by overnight courier or 

  
 -26-

 
certified or registered mail, return receipt requested, to the address specified below or such other address as the receiving Party specifies in writing, and will be effective upon its mailing as
specified. 

  
 -27-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  

			
		
	 To ERS :
	  	 Elevance Renewable Sciences Inc.

175 E. Crossroads Parkway,

Bolingbrook, Illinois 60440

Attn: [***]
 Ph: [***]
 Fax: [***]

		
	 with a copy (which shall not constitute notice) sent to:
	  	 Elevance Renewable Sciences Inc.

175 E. Crossroads Parkway,

Bolingbrook, Illinois 60440

Attn: [***]
 Ph: [***] Fax: [***]

		
	 To Stepan:
	  	 Stepan Company

22 West Frontage Road

Northfield, IL 60093

Attn: [***]
 V.P. Business Management-Surfactants
 Ph: [***]

Fax: [***]

		
	 with a copy (which shall not constitute notice) sent to:
	  	
 Stepan Company

22 West Frontage Road

Northfield, Il 60093

Attn: [***]
 V.P. and General Counsel
 Ph: [***]

Fax: [***]

  
 14.4. Assignment. This
Agreement shall be binding on the Parties and their respective successors and permitted assigns. Neither Party may assign its rights or delegate its duties under this Agreement either in whole or in part without the prior written consent of the
other Party, which consent shall not be unreasonably withheld or delayed. Any attempted assignment or delegation without such consent will be void. Notwithstanding the foregoing, either Party may freely assign this Agreement to a purchaser or
successor in connection with a merger, reorganization, or sale (whether by sale of stock, assets, or otherwise) of all or substantially all of the business of the assigning Party to which this Agreement relates, without first obtaining the consent
of the other Party, except any such assignment shall not affect a Party’s right to terminate this Agreement pursuant to Section 11.2(b).  

  
 -28-

 14.5. Severability. If any provision of this Agreement is determined to be invalid or
unenforceable the remaining provisions of this Agreement shall not be affected thereby and shall be binding upon ERS and Stepan and shall be enforceable and such provision shall be reformed to the extent necessary to render such provision valid and
enforceable and to reflect the intent of the Parties to the maximum extent possible under applicable law. 
  

14.6. Waiver of Default. The failure by either Party to insist upon strict performance of any of the provisions contained in this
Agreement shall not constitute a waiver of its rights, at law or in equity, or a waiver of any other provisions or subsequent default by the other Party in the performance or compliance with any of the terms and conditions set forth in this
Agreement. 
  
 14.7. Relationship of Parties.
Each Party is an independent contractor of the other and neither Party nor any employee, agent or contractor of such Party shall be considered a partner, joint venturer, joint employer, principal, agent, or employee of the other Party. 

 
 14.8. Governing Law. This Agreement is to be
governed by and construed in accordance with the internal laws of the State of Illinois, excluding that body of law pertaining to conflict of laws. 
  

14.9. Jointly Drafted; Review by Counsel. The Parties have participated jointly in the negotiation and drafting of this Agreement
and have had the opportunity to review the Agreement with counsel of their choosing. In the event an ambiguity or question of intent or interpretation arises, no presumption or burden of proof will arise favoring or disfavoring any Party by virtue
of the authorship of any of the provisions of this Agreement. 
  
 14.10. Licenses in Bankruptcy. Each Party specifically acknowledges and agrees that any Intellectual Property licensed by it hereunder constitutes “intellectual property” for purposes of
the United States Code, Title 11, Section 365(n). In the event of a Party’s bankruptcy and a subsequent rejection or disclaimer of this Agreement by a bankruptcy trustee or by such Party as a debtor-in-possession, whether under the law of
the United States or elsewhere, or in the event of a similar action under applicable law, the other Party may elect to retain its licensed rights, subject to and in accordance with the provisions of the United States Code, Title 11,
Section 365(n) or other applicable law. Notwithstanding the fact that other matters that may be subject to rejection or disclaimer are being addressed in connection with this Agreement, the Parties acknowledge and agree that it is the
Parties’ intent that United States Code, Title 11, Section 365(n) shall continue to apply with respect to any Intellectual Property licensed to a Party hereunder in the event of a rejection or disclaimer of this Agreement by a bankruptcy
trustee or by the other Party as a debtor-in-possession. 
  
 14.11. Further Assurances . Without limiting anything set forth in Article 6 or otherwise in this Agreement, each Party hereby agrees that from time to time, at the request of the other
Party and without further consideration, it shall execute and deliver such other documents and take such other actions as the other Party may reasonably request and are reasonably necessary to implement this Agreement or to protect or perfect the
Parties’ respective rights hereunder. 

  
 -29-

 14.12. Counterparts. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original of this Agreement and all of which together shall constitute one and the same instrument. 
  

14.13. Force Majeure. No Party shall be considered in default or will be liable for any delay in performance or for any
non-performance caused by circumstances beyond the reasonable control of such Party, including acts of God, explosion, fire, flood, accident, strike or other labor disturbance, war, sabotage, order or decree of any court or action of any
governmental authority that cannot reasonably be controlled by the Party who failed to perform, and any time periods for performance set forth herein shall be tolled for the duration of any event arising from such circumstances. 

 
 [SIGNATURES APPEAR ON FOLLOWING PAGE] 

  
 -30-

  
 IN WITNESS
WHEREOF, the Parties, by their respective authorized representatives, have signed this Agreement as of the Effective Date. 
  

									
	 ELEVANCE RENEWABLE SCIENCES, INC.
	 		 	 STEPAN COMPANY

					
	By:	 	 /s/    K’Lynne
Johnson        
	 		 	 By:
	 	 /s/    John V. Venegoni
        

	 Name:
	 	 K’Lynne Johnson
	 		 	 Name:
	 	 John V. Venegoni

	 Title:
	 	 CEO
	 		 	 Title:
	 	 VP and GM

  
 -31-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

EXHIBIT A 
  

Fields 
  

The Surfactants Field shall be defined as and limited to (a) evaluation and use (subject to a Joint Development Plan) of specific Product(s) as
feedstocks (b) derivatized via one or more of the following chemical reactions, and (c) for use in one or more of the market application areas specified below: 

 
 Surfactant Types: 

 
 [***] 

  
 -32-

  
 EXHIBIT B

  
 Screening Milestones 

  
 -33-

  
 EXHIBIT C

  
 Joint Development Plan 

 
 Executive Teams 

 
 Technical Coordinators 

 
 Joint Development Activity Field 

 
 Joint Development Objectives and Expected Results 

 
 ERS and Stepan Inputs 

 
 Testing 
  
 Products to be Utilized 
  

Derivatives to be developed and/or evaluated 
  

Expected Results 
  

Value Sharing 
  
 Exclusivity Fee 
  

Development Milestones 
  

Commercial Milestones 

  
 -34-

 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. The
text has been separately filed with the Securities and Exchange Commission. 
  
  

EXHIBIT D 
  

[***] 

  
 -35-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]